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Abstract 
 
Capsular contracture is both a physically and psychologically debilitating disease characterised by 
fibrosis and contraction of the breast capsule which can affect woman with mammary implants. 
Incidence is higher in women undergoing breast reconstruction and radiotherapy following breast 
cancer. There is evidence that Angiotensin II (Ang II) is implicated in pathological wound healing 
and blockers of Ang II may help in preventing fibrosis. The hypothesis of the study was that 
angiotensin receptors may be involved in the aetiology and development of capsular contracture 
disease. Therefore, identifying and blocking these receptors with ACE inhibitors may prevent 
fibrosis around mammary implants, providing a potential pharmacological treatment of this disease. 
Capsules from 12 breasts excised from eight patients undergoing surgery for capsular contracture in 
the Department of Plastic Surgery at Royal Preston Hospital were harvested. Tissue from each 
patient was dissociated into myofibroblasts using collagenase and cultured to determine growth 
patterns. Expressions of myofibroblasts and AngII receptors (AT1 and AT2) within breast capsule 
tissue were also investigated using immunohistochemistry. Staining of paraffin sections in the first 
four patients was poor and therefore, cryostat sections were also prepared for the second half of the 
study. An in vitro cell culture model was also designed to endeavour in the measurement of fibrotic 
contraction of cultured breast capsule fibroblasts to allow possible therapeutic interventions to be 
investigated. 
The results show that myofibroblasts were present in all capsules (n=12). AT1 and AT2 receptors 
were presented in 50% (n=6) of capsules (paraffin and cryostat sections). However, in the cryostat-
only group, staining was positive in 100% (n=5) of capsules. The results also showed that 
expressions of these receptors were co-localised with α-sma uptake demonstrating the key 
components of the RAS are present within breast capsule myofibroblasts. A higher expression and 
wider distribution of AT2 receptors were also noted compared with AT1 receptors. Solidification of 
3D gel collagen lattices was suboptimal for consistent measurements of contraction. 
In conclusion, the results presented in this thesis have identified the presence of myofibroblasts in 
breast capsule tissue and have demonstrated that they are amenable to culture successfully. 
Moreover, these myofibroblasts contain both AT1 and AT2 receptors. Further experiments are 
required to study the role of blocking AT1 and AT2 receptors excitation-contraction coupling 
process of the myofibroblasts. This study may provide the basis for a safe and cheap therapeutic 
strategy with which to modify capsular contracture affecting women with mammary implants. 
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Introduction 
 
1.1  Breast cancer 
1.1.1  Epidemiology 
 
Worldwide, more than a million women are diagnosed with breast cancer every year. It is the most 
common cancer diagnosed in the UK, despite that it is rare in men. In 2009, 48,417 women and 371 
men in the UK were diagnosed with breast cancer (Cancer Research UK, 2012). 
Female breast cancer incidence is strongly related to age, with the highest incidence rates overall 
being in older women, supporting a link with hormonal status. Overall, female breast cancer 
incidence rates have increased for all age groups in Britain over the last 40 years. Nearly half (48%) 
of female breast cancer cases are diagnosed in the 50-69 age group therefore women aged 50-70 are 
invited to attend National Breast Screening (see Table 1) 
 
Table 1.1: Estimated risk of developing breast cancer by age, females, UK, 2008 (Taken from 
Cancer Research UK). 
Estimated risk at birth up to and including: UK (2008) 
age 29   1 in 2,000 
age 39   1 in 215 
age 49   1 in 50 
age 59   1 in 22 
age 69   1 in 13 
Lifetime risk     1 in 8 
 
Risk factors for breast cancer include early menarche, low parity, late menopause, exposure to 
exogenous hormones, previous breast cancer, family history (one in 450 women carry a BRCA gene 
mutation), increased Body Mass Index (BMI), alcohol consumption and smoking (Bissel et al., 
2001). 
Unlike most other cancers, prognosis increases with age, with lower survival rates for younger 
women diagnosed with breast cancer. It has been suggested that this is because the types of breast 
cancer diagnosed in pre-menopausal women tend to be more aggressive. The five-year relative 
survival rates for breast cancer in the UK from 2005-2009 ranged from 84% in the 15-39 year age 
group to a peak of 90% in those aged 50-69 years, then decreasing gradually to 69% in 80-99 year 
olds (Cancer Research UK, 2012). 
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Breast cancer is a complex and heterogeneous disease, comprising multiple tumour entities 
associated with distinctive histological patterns and different biological features. Invasive ductal 
carcinoma and invasive lobular carcinoma constitute the majority of breast cancer (Fig 1.1) 
(Langstein et al, 2003). 
 
 
Figure 1.1: A photomicrograph of a Grade III invasive ductal carcinoma with prominent and 
pleomorhic cell nuclei and increased number of cell mitoses (kindly provided by Royal Preston 
Hospital histopathology department).  
 
1.1.2  Breast cancer treatment 
 
Treatment for breast cancer is guided by the tumour type, grade, stage, size, hormone receptor 
status and the patients’ general health. Treatments for breast cancer include surgery, radiotherapy, 
chemotherapy, hormonal therapy and biological treatments. 
Mastectomy remains an integral part of the treatment for breast cancer. With an understanding of 
the psychological benefits of breast reconstruction, breast and plastic surgeons have an integral role 
in the multidisciplinary treatment of women with breast cancer. 
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Figure 1.2: A photograph showing a scar following right mastectomy for breast cancer (the patient 
is also wearing a compression garment for lymphoedema secondary to her right axillary node 
clearance). All images were obtained from the department of medical illustration, Royal Preston 
Hospitals. All patients had previously given written informed consent for photography and for the 
use of images in research, teaching and publications. 
 
1.2  Breast reconstruction 
 
Approximately 40% of women with breast cancer will undergo a mastectomy (Fig 1.2) and, 
according to the National Institute for Health and Clinical Excellence (NICE, 2012), all should be 
offered the chance of breast reconstruction.   
The first published breast reconstruction was performed by Czerny et al (1895) using a lipoma from 
a patient’s back to fill the defect after removal of a large benign breast mass. Breast reconstruction 
techniques have significantly advanced since with autologous pedicled flaps and microvascular 
free-tissue transfer, along with tissue expanders and breast implants, now forming the mainstay of 
21st Century breast reconstruction (Wain and Srinivasan, 2011).  
Immediate breast reconstruction during surgery for breast cancer is gaining in popularity. This is 
when breast reconstruction is performed during the same operation as the mastectomy. It is 
considered oncologically safe and can be performed in patients who require post-operative 
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radiotherapy (Langstein et al, 2003). Some women find that immediate reconstruction helps them 
cope with the loss of a breast.  
Delayed reconstruction occurs anytime after four months from initial mastectomy. This allows 
patients to undergo, and recover from, adjuvant radiotherapy and/or chemotherapy prior to breast 
reconstruction (Wain and Srinivasan, 2011). The overall aims of breast reconstruction are to create 
a breast mound, to achieve a normal and symmetric silhouette, to limit patient morbidity, and to 
avoid the need for an external breast prosthesis.  
 
1.2.1  Autologous breast reconstruction techniques 
 
Breast reconstruction with autologous (patient’s own) tissue can involve pedicled and free tissue 
transfer, with or without an implant (Fig 1.3). Pedicled flaps remain connected to their native 
arterial and venous supply whilst the tissue is transferred to a new anatomical location whereas, free 
flaps are completely disconnected from their original blood supply and the vessels are anastomosed 
using micro-surgical techniques to recipient blood vessels (Saint-Cyr and Schaverien, 2008). 
Techniques include the ‘Latissimus Dorsi (LD) Flap’, the ‘Transverse Rectus Abdominis 
Myocutaneous (TRAM) Flap’, the ‘Deep Inferior Epigastric Perforator (DIEP) flap’ (Fig 1.3) and 
the ‘Superficial Inferior Epigastric Artery (SIEA) flap’ (Janis, 2007). Autologous tissue 
reconstruction (Fig 1.3) has the advantage of a more natural appearance and texture compared to 
implant-based reconstructions (Fig 1.4). Autologous reconstruction (Fig 1.3) is particularly 
beneficial in patients who require post operative radiotherapy, for those who prefer not to have a 
silicone implant, or in cases where implant reconstruction has been previously unsuccessful (Saint-
Cyr and Schaverien, 2008). 
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Figure 1.3: A photograph to show a patient who has undergone autologous left breast 
reconstruction, following breast cancer, using a deep inferior epigastric perforator (DIEP) free-flap.  
 
1.2.2  Prosthetic (implant) reconstruction techniques 
 
A survey in 2009 of the American Society of Plastic Surgeons (ASPS) revealed that of 
86,424 breast reconstructions performed, 66,075 (76%) were implant based (ASPS, 2009). 
Prosthetic techniques include fixed volume implants, variable volume expander-implants and tissue 
expanders (which can be inflated over a number of weeks to increase the size the pocket) and 
subsequent exchange for implant. Breast implants consist of a filler material, either silicone or 
saline, inside a silicone elastomer shell. The shell can be either smooth or textured. Breast implants 
are regulated as medical devices. The Medicines and Healthcare products Regulatory Agency 
(MHRA) is responsible for ensuring that breast implants meet appropriate standards of safety, 
quality and performance, and that they comply with the Medical Devices Directive (MHRA, 2012). 
When planning implant-based reconstruction, consideration of the amount skin, subcutaneous tissue 
and muscle, and whether post-operative radiotherapy is required, are important as insufficient soft 
tissue coverage will give poor cosmetic results. Implant-based breast reconstruction is ideally suited 
to reconstruct small to moderate breasts with none or mild ptosis. Patients with a normal body-max 
index and intact pectoralis major muscle are ideal candidates. Prosthetic techniques are also useful 
for patients undergoing bilateral breast reconstruction and for those patients who are not suitable to 
undergo autologous tissue reconstruction (Wain and Srinivasan, 2011). The most frequent 
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complication associated with the reconstruction using a breast prostheses, especially those filled 
with silicone, is the onset of fibrous capsular contraction (Fig 1.4). 
 
1.3  Capsular contracture 
 
As part of the physiologic response to a foreign material (antigen), the body also reacts by forming 
a fibrous capsule around the material (i.e. the breast implant) that is too large to be phagocytised 
and too inert to produce a toxic reaction (Embrey et al., 1999). Why this biologically normal 
capsule around a mammary prostheses contracts in some women resulting becoming hard, tight and 
painful is yet to be determined (Shiffman, 2009).  
Capsular contraction following implantation of breast prostheses occurs in 2–33% of patients 
undergoing breast augmentation (Singh-Ranger and Mokbel, 2004). Most surgeons quote a figure of 
5- 20% in pre-operative breast augmentation counselling (Shiffman, 2009). This complication can 
develop weeks or years after implantation of breast prosthesis however, approximately 60% of 
capsular contracture occurs within six months and 90% within 12 months postoperatively 
(Shiffman, 2009). Women who have undergone more complicated procedures, such as mastectomy 
with breast reconstruction, are reported to have higher rates of contraction than women who have 
undergone simple breast augmentation alone (Handel et al., 1995). 
This complication is a huge problem for breast cancer patients undergoing reconstructive surgery. 
The condition can be debilitating for patients causing significant pain and distortion of the 
appearances of the reconstructed breast causing further emotional stress (Fig 1.4).  
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Figure 1.4: Two photographs showing two patients (A and B) with capsular contracture following 
breast reconstruction using implants. A: left-side Baker grade IV and right-side grade III capsular 
contracture. The capsule has contracted distorting the shape of the breast; B: asymmetry and severe 
deformity of the right reconstructed breast due to grade IV capsular contracture. 
A 
B 
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1.3.1  Classification of capsular contracture 
The severity of capsular contracture is classified by Baker’s Classification as shown in Table 2. 
There are four grades of breast capsular contracture - Baker grades I through IV. For this system, a 
soft but visible implant (grade I) and an implant with mild firmness (grade II) are considered good 
or excellent outcomes. An implant with moderate firmness (grade III) may require treatment if 
symptomatic and class IV classification, with an excessively firm and symptomatic breast result in a 
significantly poor aesthetic result (Spear and Baker, 1995). 
 
Table 1.2: Baker’s classification of capsular contracture. 
Baker Grade Clinical Findings 
Grade I breast is normally soft and looks natural 
Grade II breast is a little firm but looks normal 
Grade III breast is firm and looks abnormal 
Grade IV breast is hard, painful, and looks abnormal 
 
 
 
1.3.2  Aetiology of capsular contracture 
 
The aetiology of capsular contraction is unclear. The pathogenesis clearly involves a localised tissue 
inflammatory response. The fibrous capsule may be a normal response to a foreign body but may be 
related to factors such as bacterial infection, excessive bleeding at the time of surgery, or ongoing 
inflammation and fluid accumulation. It is more common in women who undergo immediate breast 
reconstruction during surgery for breast cancer and tends to be more severe. Capsular contracture is 
also more likely if patients have radiotherapy before or after reconstruction with a breast implant 
(Embrey et al., 1999).  
This process occurs over many months and years. Lack of knowledge of the cellular mechanisms 
governing this process makes pharmacological therapy difficult (Kamel et al, 2001). However, 
many theories have been proposed: 
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1.3.2.1  Bacterial infection 
 
There is increasing evidence for the role of microorganisms in the pathogenesis of capsular 
contracture (Shiffman, 2009). Bacterial colonization or subclinical infection of the capsule around 
an implant may stimulate contraction through immune processes. Bacterial contamination has also 
been shown to stimulate fibroplasia and contraction in wounds (Embrey et al., 1999; Shiffman, 
2009). 
Several authors have reported positive microbiology cultures, particularly coagulase negative 
staphylococcus epidermis, from breast pockets prior to the insertion of breast prosthesis and also 
from the majority of fibrous capsules submitted for culture. However, studies have not correlated 
cultures from capsules with the subjective assessment of clinical firmness (Embrey et al., 1999; 
Shiffman, 2009). Peri-operative prophylactic antibiotics have been shown to reduce the incidence of 
implant infection further supporting this hypothesis (Becker et al, 1999).  
 
1.3.2.2  Placement of the implant 
 
The extensive literature on capsular contracture supports submuscular placement to decrease the 
incidence of capsular contracture. The exact mechanism is unknown however, the continuous 
massage provided by the muscle may keep the capsule soft and pliable (Shiffman, 2009). However, 
it is likely that the layer of muscle over the capsule also masks any capsular contracture as it is more 
difficult to appreciate. Also, with submuscular placement, there is decreased potential for 
haematoma formation and contamination of the implant due to decreased vascularity of this plane 
when compared with the subglandular plane (Becker et al, 1999).   
 
1.3.2.3  Type of implant 
 
It is thought that a smooth implant surface results in less bacterial adhesion than textured implants, 
reducing the potential for infection which is known to play a role in capsular contracture (Embrey et 
al., 1999; Becker et al, 1999). Adjustable implants, used to over-expand the pocket followed by 
volume reduction several weeks later have also been associated with a lower incidence of 
contracture (Becker et al, 1999). 
 
1.3.2.4  Haematoma  
 
Haematoma (a collection of blood outside the blood vessels within the tissues) is known to 
predispose patients to forming a capsular contracture (Embrey et al., 1999). Intra-operative bleeding 
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should therefore be minimised. Post-operatively compression dressings can be applied to reduce 
bleeding from small vessels once epinephrine-induced vasoconstriction wears off. Patients should 
avoid over-activity for at least two-weeks following surgery to prevent haematoma (Becker et al, 
1999). 
 
1.3.2.5  Smoking 
 
Smoking is known to impair wound healing and is associated with a higher incidence of post- 
operative infection. Patients should be advised to stop smoking and refrain from using nicotine 
patches, for at least four weeks pre and post operatively (Becker et al, 1999). 
 
1.3.3  Histological characteristics of breast capsules 
 
Early basic histological studies of breast capsules suggested that they were simply laminated 
collagen with limited cellularity largely consisting of fibroblasts, myofibroblasts occasional 
mononuclear cells and lymphocytes (Baker, 1981). Contemporary analyses of capsules however, 
demonstrate a more sophisticated histological structure composed of three distinct layers (Shiffman, 
2009). The internal layer, adjacent to the prosthesis is either single or multi-layered and consists of 
macrophages and fibroblasts. The middle layer is formed from loosely arranged connective tissue 
containing an internal vascular supply whilst the third layer is composed of dense connective tissue 
with an external vascular supply. In 60% of patients, an inner layer of synovial-like metaplasia 
consisting of mononuclear macrophages and multinucleated giant cells is also described. Chronic 
inflammation is present in 90% of capsules (Granchi et al., 1995; Shiffman, 2009).  
Large amounts of silicone are associated with increased local inflammation (Prantl et al, 20007). 
Silicone is present in most capsules, usually confirmed by vacuolated macrophages containing 
refractory material. It has been identified in the capsules surrounding both silicone and saline-filled 
implants. The origin is thought to be frictional from shearing forces on the silicone elastomer 
implant envelope. It has been shown that the thickness of the capsule is positively correlated with 
increasing levels of free silicone (Granchi et al., 1995; Shiffman, 2009).  
Prantl et al (2007) investigated the histological changes in capsules formed around silicone breast 
implants and their correlation with the clinical classification of capsular contracture defined by the 
Baker score. They found a positive correlation between capsule thickness and Baker score and also 
showed a trend toward greater capsular thickness in patients with a more severe inflammatory 
reaction. 
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1.3.4  Current treatment of capsular contracture 
 
Once established, capsular contracture is difficult to treat. Treatment of capsular contracture usually 
requires surgical removal (Fig 1.5) or release of the scar around the implant and often replacement 
of the implant itself. The rate of recurrence of capsular contracture after surgery is high (Shestak, 
2006). Treatment is often life-long and can involve multiple operations. 
Conservative treatment modalities include breast compression exercises which may prevent 
contracture progression and help to keep the capsule soft and pliable. Breast massage, in particular 
quadrant massage, also helps to maintain a softer capsule and ultrasound from an external source 
has also been used, with little effect, to soften and reduce contractures (Shestak, 2006). 
 
Surgical options for treatment of capsular contracture include capsulectomy and capsulotomy. 
‘Otomy’ means to release scar tissue in Latin.  During ‘capsulotomy’ the breast capsule is simply 
opened with an electrocautery device to release the implant from contracture and allow for 
expansion. In capsulectomy, the entire constricting capsule is excised removed during the procedure 
(Fig 1.5). This is the most effective method of relieving all symptoms and preventing a recurrence 
(Broughton et al., 2006). Capsulotomy is only appropriate in some circumstances, such as for 
patients with minimal breast tissue in who complete excision of the capsule may result in visibility 
of the implant itself. However, this technique is generally less effective than full excision of the 
capsule. Closed capsulotomy uses manual pressure to break the contracture. This is a painful and 
dangerous procedure which is no longer advised.  
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Figure 1.5: A photograph showing a thick fibrous breast capsule from patient 3 following 
capsulectomy and explantation of silicone breast prosthesis for severe grade IV capsular contracture 
(photograph taken intra-operatively with informed written consent from the patient). 
 
1.4.1  The Process of Wound Healing  
 
There are three phases of wound healing. Although these phases overlap they are biologically 
distinct. The initial inflammatory phase consists of haemostasis with formation of a clot, removal of 
devitalised tissue and prevention of infection. This is followed by the second proliferative phase 
during which the provisional wound matrix is formed. During the last phase ‘remodelling’ scar 
tissue matures and wound strength is maximised (Diegelmann, 2004). 
 
1.4.1.1  Haemostasis and Inflammatory Phase (24-48hrs)   
 
The first phase lasts from the first 24 to 48 hours following wounding.  Tissue injury causes 
endothelial disruption and release of proteolytic enzymes. Haemorrhage ensues and a platelet plug 
adheres to exposed type II collagen following clotting cascades (Witte, 1997). Growth factors 
within the platelet plug (PDGF, TGF- ,) and inflammatory cytokines (fibrinogen, fibronectin, 
vWF) increase cell proliferation and migration to the area. Initial vasoconstriction is followed by 
vasodilation due to inflammatory mediators histamine, kinins and complement. This results in 
22 
 
vessel engorgement and plasma exudation into the damaged area.  PDGF, secreted by platelets 
during thrombus formation, acts as a chemo-attractant for macrophages, which remove bacteria and 
debris from the wound. Macrophages also attract fibroblasts, which migrate into the wound by 
forming cell-matrix contacts with matrix proteins (fibronectin, vitronectin, and fibrinogen). This 
migration of fibroblasts signals the start of the proliferative phase. Growth factors and proteins 
stimulate fibroblasts to synthesise collagen and extracellular matrix components (ECM) (Witte, 
1997; Diegelmann, 2004; Li, 2007).  
Within 12 hours following wounding, neutrophils and monocytes migrate into the wound. Initially 
neutrophils adhere to the vascular endothelial cell wall releasing elastase and collagenase, allowing 
migration through the basement membrane into the wound matrix where they kill bacteria by 
phagocytosis. This neutrophil response declines after a few days and monocytes are attracted by 
soluble mediators and bind the extracellular matrix via integrin receptors. Here, they differentiate 
into macrophages which function to phagocytose bacteria, devitalised tissue and depleted 
neutrophils; produce collagenase and elastase, facilitating proteolytic destruction of devitalised 
tissue and; release soluble mediators (TNF-, TGF-, PDGFs, IL-1, IL-6) which recruit and 
activate fibroblasts and promote angiogenesis (Diegelmann, 2004; Li, 2007). 
 
1.4.1.2  Proliferative Phase: (Day 3 up to 4 weeks) 
 
During the second stage of wound healing the provisional wound matrix is remodelled and replaced 
by scar tissue. This consists of collagen, proteoglycans and elastin fibres. During this phase, 
epithelial cells, fibroblasts and vascular endothelial cells migrate to the wound site and proliferate. 
Fibroblasts also actively produce type III collagen. The early collagen is disorganised and wound 
tensile strength is poor. Fibroblasts also lay down extracellular matrix to strengthen the wound, 
increasing its tensile strength. The process of angiogenesis occurs concurrently with fibroblast 
proliferation and granulation tissue, consisting of capillary loops and surrounding collagen fibres, is 
formed (Diegelmann, 2004; Li, 2007). The formation of granulation tissue into an open wound 
allows re-epithelialisation phase to take place. Epithelial cells migrate across the new tissue to form 
a barrier between the wound and the environment. Basal keratinocytes from the wound edges and 
dermal appendages such as hair follicles, sweat glands and sebaceous glands are the main cells 
responsible for the epithelialisation phase of wound healing. (Diegelmann, 2004; Li, 2007). 
 
1.4.1.3  Remodeling Phase (21 days- 1 year) 
 
The final, and longest, phase of wound healing starts from day 21 up to one year. It commences 
once the wound defect has been replaced by granulation tissue and re-epithelialisation has been 
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completed by migrating keratinocytes.  The precise mechanisms by which this takes place are not 
fully understood however, it is proposed that during this phase collagen remodelling, wound 
contraction and, a progressive decrease in scar vascularity occur (Witte 1997). During collagen 
remodelling, type III collagen is slowly degraded and replaced by type I collagen (normal dermis 
contains mainly type I collagen). Collagen synthesis peaks at five to seven weeks, although 
increased synthesis and degradation continue for up to one year. There is also increase collagen 
cross-linking subsequently increasing the tensile strength of the wound. Wound contraction is 
produced by myofibroblasts (fibroblasts with actin filaments capable of matrix contraction). 
 
1.4.2.  Wound contraction 
 
Following surgical injury, such as breast reconstruction, new connective tissue is synthesized and 
mesenchymal fibroblasts become activated. (Gabbiani, 2003). These wound fibroblasts, located at 
the site of injury, synthesise a skeleton matrix of collagen type III, glycosaminoglycans and 
fibronectin which are responsible for wound contraction. 
Wound contraction, a process by which wound edges move together to minimise dead space, begins 
four to five days post wounding and continues for approximately 12-15 days at an average rate of 
0.6-0.75 mm per day (Tejero-Trujeque, 2001). The healing of a wound is dependent on two key 
phenomena: i) epithelialisation; and ii) formation of granulation tissue (Gabbiani, 2003). Wound 
healing ends with scar formation as a result of permanent deposition of connective tissue. This is 
characterised by the presence of extracellular matrix components among which collagen is the most 
important, fibroblasts and small vessels (Gabbiani, 2003). 
At the end of normal wound healing process, when epithelialisation has been achieved, granulation 
tissue disappears and the contractile and synthesizing activity of myofibroblasts is usually 
terminated. The cell number is dramatically reduced by apoptosis. (Desmouliere et al., 1995). 
1.4.2.1  Pathological wound contraction 
 
Wound contraction permits wound closure however, excessive contraction can produce functional 
and aesthetic problems. It is generally considered that fibrotic disease processes occur due to failure 
of the normal wound-healing response (Zinmann et al, 2007). In chronic pathological contracture 
diseases, the process of massive apoptosis is absent and the contractile and synthesising activity 
continues leading to soft tissue deformation (Gabbiani, 2003). In these pathological scarring 
processes, the excessive extracellular matrix deposition may continue for several years. (Gabbiani, 
2003). These pathological phenomena can lead to life threatening fibrosis when affecting organs 
such as the heart lungs and kidneys.   
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1.5  The Myofibroblast 
 
Gabbiani et al (1971) first described a certain type of fibroblast, the myofibroblasts, as the cell 
responsible for contraction of granulation tissue exhibiting an important cytoplasmic 
microfilamentous apparatus (Gabbiani, 2003). They defined the myofibroblast as a cell with the 
intermediate morphological characteristics of a fibroblast and smooth muscle cell as they contain 
smooth muscle actin (α-SMA) (Desmoulière et al., 2005). 
The myofibroblast has been identified both in normal tissues, particularly in locations where there is 
a necessity of mechanical force development, and in pathological tissues, in relation with 
hypertrophic scarring, fibromatoses and fibro-contractive diseases (Klingberg et al., 1988).  
The myofibroblast capacity for generating a contractile force is well documented. This contractile 
force generated by the myofibroblast during wound healing is beneficial for tissue remodelling 
however, it becomes detrimental when it becomes excessive such as in hypertrophic scarring, 
fibrotic disease and capsular contracture (Hinz, 2007).  
 
1.5.1  Features of the myofibroblast 
 
Three distinct structural components distinguish the activated myofibroblast from the inactive 
fibroblast.  
 Bundles of contractile microfilaments 
 Extensive cell-to-matrix attachment sites 
 Intracellular adherans and gap junctions  (Eyden, 2005; Hinz, 2007) 
Fibroblast-to-myofibroblast differentiation represents a key stage during wound healing after injury 
and tissue repair (Gabbiani, 1992). This differentiation of fibroblasts into myofibroblasts is 
described as a two stage process:  
1. Fibroblasts acquire a migratory phenotype by de novo and develop contractile bundles to re-
populate damaged tissues.  This phenotypic change occurs in response to changes in the 
composition, organisation and mechanical properties of the extracellular matrix and to 
cytokines released by inflammatory cells (Hinz, 2007). This ‘activated myofibroblast’ has 
previously been described as a 'proto-myofibroblast’ (Tomasek et al., 2002). 
2. The ‘proto-myofibroblasts’ develop into ‘differentiated myofibroblasts’ by expressing α-
smooth muscle actin (Hinz, 2007). This expression is regulated by the action of growth 
factors including transforming growth factor (TGFβ1), ECM proteins and by the mechanical 
micro-environment (Tomasek et al., 2002). The contractile activity of fibroblasts is 
amplified as α-SMA is incorporated into stress fibres and this characterises the contractile 
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phase of tissue remodelling (Hinz et al., 2001). The contraction action of myofibroblasts 
during remodelling ceases when the tissue is repaired. The expression of α-SMA terminates 
and myofibroblasts are removed by apoptosis (Desmouliere et al., 1995).  
 
 
Figure 1.6: Schematic diagram showing myofibroblast regulation (Taken from James et al, 2002). 
 
1.5.2  Myofibroblast regulation 
 
Two key factors have been implicated in the regulation of the myofibroblast: Transforming Growth 
Factor (TGF-1) and mechanical tension on a wound. Injection of TGF-1 in a rat wound healing 
model lead to formation of granulation tissue containing activated myofibroblasts (Katwa et al., 
1998). Fibroblasts cultured under tension differentiate into myofibroblasts which produce smooth 
muscle actin bundles. However, when cultured in a relaxed state these actin bundles are absent 
which suggests wound tension has a role in regulating myofibroblast population (Hinz et al., 2001) 
After wound healing and re-epithelialisation occurs, there is mass myofibroblast apoptosis (Hinz, 
2007). The exact mechanism for myofibroblast suicide is unclear although the mechanisms of cell 
release from stress and increased formation of specific cell-cell contacts have been advocated.  
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In animal models, myofibroblast apoptosis has been demonstrated to be inhibited by preventing the 
tension release of granulation tissue by splinting the wound. Myofibroblast apoptosis has also been 
induced by releasing fibroblast-attached collagen gels in vitro (Hinz, 2007). 
 
1.5.3  Myofibroblast markers 
 
Alpha- smooth muscle actin is the most widely recognised myofibroblast marker. However, its 
limitations are that it fails to differentiate between vascular smooth muscle cells (SMC) (elongated 
contractile cells that form the smooth muscles of the body) and myofibroblasts when the population 
is mixed (Hinz, 2007). Ronty et al (2006) proposed an innovative marker for myofibroblast 
differentiation: the 41 g isoform of the stress fibre protein paladin. However, this has also shown to 
be expressed by SMC therefore a cytoskeletal protein which can discriminate between SMC and 
myofibroblasts remains to be determined (Hinz, 2007). The myofibroblast also expresses specific 
proteins on its surface. These have importance for the targeting of specific drugs (Hinz, 2007). For 
example, the plasma membrane protein Thy-1 is present on the membrane of fibroblasts but absent 
in myofibroblasts. More recently, Hinz and Gabbiani (2003) suggested a novel approach to identify 
myofibroblasts by their expression of specific cadherins (transmembrane cell-cell adhesion proteins 
linked intracellularly to the actin cytoskeleton) (Hinz, 2007). These myofibroblast-specific proteins 
provide potential targets to modulate myofibroblast contractility to target fibrosis.  
 
1.5.4  Role of the myofibroblast in capsular contracture 
 
Several authors have investigated the significance of the myofibroblast in capsular contracture. 
Gabbiani et al (1971) described the presence of contractile myofibroblasts in granulation tissue and 
associated it with contraction processes. Zimman et al (2002), using electron microscopy, 
investigated the fibrous envelope around mammary implants and found the contractile 
myofibroblasts within collagen fibre inside the fibroblast cytoplasm (collagen fibre is produced 
normally in the extracellular space). Baker et al (1981) identified myofibroblasts in several breast 
capsules. They hypothesized that myofibroblasts execute contraction of the developing breast 
capsule by means of a ratchet-like mechanism composed of collagen and cross-linking. They also 
suggested that the contractile site is maintained by the adherent properties of the Extracellular 
Matrix (ECM), which provides the structural component of cells, in which a network of collagen 
fibres is imbedded.  Hwang et al (2010) showed that the tensile strength of the breast capsule 
correlated with the degree of capsular contracture. They proposed that during capsule formation, 
myofibroblasts appear during an active phase of wound contraction and diminish when the wound 
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becomes matured. These data support the hypothesis that the myofibroblasts are a probable cause of 
capsular contracture. 
 
1.5.5  The Extracellular Matrix (ECM) 
 
The extracellular matrix (ECM) is the largest component of normal skin. It gives skin properties 
such as elasticity, compressibility and tensile strength. In acute wounds the provisional wound 
matrix, containing fibrin and fibronectin, acts as a scaffolding to direct cells to the site of injury as 
well as to stimulate cell differentiation and the production of new ECM. The synthesis of ECM is a 
key feature of wound healing (Frantz et al, 2010). 
 
The constituents of ECM include polysaccharides, water, collagen and proteins. The two main 
classes of ECM molecules are: 
1. Fibrous structural proteins, which give the ECM strength (collagens, elastin, laminin) 
2. Proteoglycans, which consist of multiple glycosaminoglycan chains that branch from a 
linear protein core. These are large, highly hydrated molecules that help cushion cells in the 
ECM. (Schultz et al., 2005) 
 
Enhanced ECM synthesizing activity significantly contributes towards tissue remodelling (Hinz, 
2007). Myofibroblasts produce several components of the ECM such as collagen types I, III, IV and 
V (Schurch et al., 2006). Capsular contraction is characterized by excessive scarring resulting from 
excessive production and deposition of extracellular matrix (Zinmann et al., 2007). 
1.6   The Renin-Angiotensin System (RAS) 
 
Renin (REN) was first discovered as a pressor substance in 1898 (Lavoie and Sigmund, 2003). 
Angiotensin-II (AngII) is produced by an enzymatic cascade. Angiotensinogen (AGTN) is cleaved 
by REN, an aspartyl protease to form the decapeptide angiotensin I (Ang-I). Ang-I is then further 
cleaved by angiotensin-converting enzyme (ACE), a dipeptidyl carboxypeptidase, to produce 
Angiotensin II (AngII) the active biological octapeptide of the systemic renin-angiotensin system 
(Hikaru et al.,2004; Lavoie and Sigmund, 2003). This circulating humoral system is responsible for 
blood pressure regulation and salt-water homeostasis. Further degradation (or processing) by 
aminopeptidase A and N produce angiotensin III (Ang 2–8), and angiotensin IV (Ang 3–8) 
respectively (Lavoie and Sigmund, 2003). 
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Figure 1.7:  Flow diagram demonstrating the REN-angiotensin cascade (Taken from Lavoie and 
Sigmund, 2003).  
 
The role of Angiotensin II (AngII), the physiologically active component and end-product of the 
RAS, in the control of systemic blood pressure and volume homeostasis is well described (Lavoie 
and Sigmund, 2003). The properties of Angiotensin II (Ang-II) include vasoconstriction, regulation 
of renal sodium and water absorption, and increasing thirst (Lavoie and Sigmund, 2003).  
These effects of AngII on blood pressure regulation were first thought to be mediated primarily 
through blood-borne angiotensin with actions in target tissue, known as the classical endocrine 
pathway. However, more recently, it has become appreciated that a local autocrine or paracrine 
RAS may also exist within tissues and that these may also play a significant role in blood pressure 
homeostasis (Lavoie and Sigmund, 2003). 
Two major AngII receptors, namely Ang-II type I (AT1) and Ang-II type (AT2) have been 
identified (Timmermans et al, 1993). Ang II causes vasoconstriction both directly and indirectly by 
stimulating (AT1) receptors present on the vasculature and by increasing sympathetic tone and 
arginine vasopressin release (Lavoie and Sigmund, 2003). Ang-II also maintains blood pressure 
homeostasis by regulating renal sodium and water reabsorption directly by stimulation of  AT-1 
receptors in the kidney, and also indirectly by stimulation of the production and secretion of 
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aldosterone from the adrenal glands and by activating the thirst centre in the central nervous system 
(CNS). 
 
1.6.1  The ‘Classical’ role of Angiotensin 
 
 Ang II has a well described role in remodelling and repair in various pathophysiological situations. 
Angiotensin II (Ang II) plays a pivotal role in cardiac fibrosis (Yamagishi et al, 1996). In the 
myocardium, AngII causes left ventricular hypertrophy following myocardial infarction and in 
cardiomyopathy and arterial hypertension (Zhu et al, 2003). AngII also plays a key role in the 
progression of kidney diseases, contributing to renal fibrosis by up-regulation of pro-fibrotic 
factors, induction of epithelial mesenchymal transition and accumulation of extracellular matrix 
proteins (Lavoz et al, 2012). A large body of evidence also demonstrates that Ang-II and 
angiotensin receptors are required for the pathogenesis of experimental lung, liver and pancreatic 
fibrosis (Yamada et al, 2003) 
 
1.6.2  Angiotensin in wound healing 
 
For many decades, the renin–angiotensin system has been investigated solely with regard to its 
cardiovascular and renal homeostatic actions (Campbell, 1987; Carey, 2000;  Ferder,  2003; Atlas, 
2007) . In recent years however, the conventional role of AngII has been challenged with evidence 
to suggest that this active octapeptide hormone of the RAS, is not only manufactured locally within 
tissues but also plays a key role in tissue repair, regulation of the ECM and production of fibrous 
tissue (Katwa et al., 1998; Mckirdy et al., 2001). 
Tissue RASs have been shown to be capable of the local generation of Ang II, which makes them 
independent of plasma-borne AngII and facilitates locally restricted effects (Steckelings et al, 
2005). This tissue RAS, which acts independently of the circulating renin angiotensin system, has 
been demonstrated in models of cardiac, hepatic and renal fibrosis (Lavoie and Sigmund, 2003). 
However, compared to the cardiac models, the role of AngII in skin and subcutaneous tissue is far 
less documented. AngII stimulation has been shown to regulate proliferation of skin fibroblasts and 
production of extracellular matrix; two key processes in wound healing. AngII has been proposed to 
be involved in the stages of cutaneous wound healing including increasing vascular permeability, 
recruiting inflammatory cells, cell proliferation and migration, neovascularisation and fibrosis 
(Clark, 1996, Steckelings et al, 2005).  
Evidence has also shown that AngII has fibrotic properties. It stimulates fibroblasts to synthesize 
the extracellular matrix components collagen I, fibronectin, laminin and elastin (Zhu et al, 2003; 
Sun and Weber, 1996; Sun et al., 1997). AngII has also been demonstrated to have a role in the 
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regulation of endothelial cell proliferation and differentiation and new vessel formation during 
neovascularisation (Walsh et al, 1997).  
This duality of the RAS, working simultaneously in both local tissue and endocrine systems, has 
made the system extremely complex. It’s precise action and functions are yet to be determined. In 
the advent of new technologies, we will undoubtedly continue to learn more about how this 
complex system works in vivo. 
 
1.6.3  Angiotensin receptors 
 
Two distinct AngII receptor subtypes have been cloned: AT1 and AT2 (Kaschina et al., 2003; 
Steckelings et al., 2005). In binding studies and physiological experiments, these receptors can be 
distinguished using specific antagonists. Both AT1 and AT2 are cell surface receptors belonging to 
the large family of G-protein coupled seven-transmembrane receptors (Kaschina et al., 2003; 
DeGasparo et al., 2000). However, the pathways used are very different and the AT1 and AT2 
receptors signal in apparent opposition.  AT1 receptors mediate many of the well‐known systemic 
stimulatory and physiological actions of Ang II including secretion of aldosterone, vasoconstriction, 
and renal sodium reabsorption responses whereas AT2 receptors are thought to mediate vasodilator 
responses (Lavoie and Sigmund, 2003). 
AT1 and AT2 receptors also have a wide tissue-specific distribution. They are both present in the 
kidney, brain, and adrenal gland. In general, AT1 receptors are present in adult cardiovascular 
tissues, whereas AT2 is known to be highly expressed during foetal development (Kaschina et al., 
2003; Steckelings et al., 2005).  
In animal models, AngII receptor antagonism results in a reduction in the inflammatory response 
and fibrosis in these organs and tissues. This has been demonstrated in cardiac infarction, liver 
fibrosis and interstitial nephritis. In humans, there is also reduced fibrosis post myocardial 
infarction and diabetic renal disease following ACE-inhibitor therapy which is now used routinely 
to reduce the amount of collagen deposition. 
Steckelings et al (2005) demonstrated an increased Ang II receptor expression in human cutaneous 
wounds using three different experimental approaches supporting the theory that angiotensin 
receptor expression is increased in other tissues undergoing repair and remodelling. 
 
1.6.4  Angiotensin Type 1 (AT1) receptors 
 
Pharmacological studies using specific antagonists have determined that most of the physiological 
actions of Ang-II are mediated by the AT1 receptor (such as vasoconstriction, cellular growth, 
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production of the extracellular matrix) (Timmermans et al., 1993). This receptor is also involved in 
the recruitment of inflammatory cells, angiogenesis, cell proliferation and extracellular matrix 
synthesis (Kaschina et al., 2003). 
McKirdy et al (2001) identified the presence of AT1 receptors using immunohistochemistry in 
Dupuytren’s disease. They found that these receptors were co-localised with areas of myofibroblast 
expression, which has implications for the potential of pharmacological regulation using ACE-
inhibitors to modulate contracture disease processes. Also, in AngII type 1-receptor (ATR1 knock-
out-mice) wound healing was markedly delayed (Yahata et al, 2006). 
 
1.6.5  Angiotensin type II (AT2) receptors 
 
AT1 receptor function is well described in the literature. However, AT2 receptor function has not 
yet been fully determined. Studies have suggested that the AT2 receptor function may oppose the 
actions of the AT1 receptor with respect to blood pressure and cellular proliferation (Carey et al., 
2000). It has also been suggested that AT2 receptor stimulation decreases renal tubular sodium 
reabsorption (Lo et al., 1995) 
The actions and signal transduction mechanisms initiated by AT2 receptor stimulation are proposed 
to be unconventional and quite distinct from those described for AT1 receptor-coupled events. The 
‘ying-yang hypothesis’ suggests that AT2 receptor-mediated actions counteract those of AT1 
receptor-coupled actions. These opposing actions of AngII receptors predispose the RAS to take 
part in regulatory mechanisms (Steckelings et al., 2005). This phenomenon can be seen in the 
regulation of cell proliferation by AngII and also collagen synthesis which are both stimulation via 
the AT1 receptor and inhibited via the AT2 receptor (Steckelings et al., 2005) 
 
1.6.6  AngII receptors in wound healing 
 
In tissue repair and remodelling, changes in angiotensin receptor distribution have been described 
observed in a variety of organs (Nio et al., 1995; Busche et al., 2000). During wound healing, 
migration of keratinocytes and dermal myofibroblasts are stimulated by Ang II, mediated by the 
AT1 receptor. The AT2 receptor appears to have a counteracting effect on cell migration (Takeda et 
al., 2004). Previous studies have shown that skin wound healing is regulated by the balance of 
opposing signals between AT1 and AT2. Ang II-induced stimulation of collagen production was 
mediated via the AT1 receptor, whilst the AT2 receptor had an inhibitory effect on basal collagen 
synthesis in skin fibroblasts from AT1a receptor knockout mice (Min et al., 2004; Steckelings et al., 
2005). It is thought that over-induction of AT1 signalling may contribute towards pathological 
fibrotic responses such as scarring. 
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Interestingly, the AT2 receptor, which is sparsely expressed in the vast majority of human tissues, is 
markedly upregulated during wound healing (Steckelings et al., 2005). In pathological states 
however, AT1 saturation with excess Ang II may lead to increased AT2 signalling which may 
contribute towards pathological fibrotic responses such as scarring. 
 
1.7  Angiotensin-Converting Enzyme (ACE) Inhibitors 
 
ACE is present in tissues composed largely of fibrillar collagen such as coronary arteries, adventitia 
of great vessels and intramyocardial coronary arteries as well as the scar that follows myocardial 
infarction (Katwa et al., 1995). 
ACE inhibitors are hypotensive drugs that inhibit the converting enzyme peptidyl dipeptidase, 
which hydrolyses angiotensin I to angiotensin II and inhibits the degradation of a potent vasodilator, 
bradykinin, a mechanism which at least in part, is prostaglandin mediated (Ianello, 2006). There are 
several ACE inhibitors in clinical use at present. Captopril is a sulfhydryl-containing agent 
metabolised primarily to disulfide conjugates with other sulfhydryl-containing molecules, and is 
distributed to most body tissues and excreted chiefly by the kidneys.  It has an inhibitory action on 
the renin-angiotensin system (Katwa et al., 1995; Ianello, 2006). Enalapril is a prodrug that is 
hydrolyzed in the body and converted by de-esterification to ACE inhibitor enalaprilat; it is a non-
sulfhydryl-containing agent. Lisinopril is a lysine derivative of enalaprilat, the active metabolite of 
enalapril. Fosinopril and ramipril, next introduced, are slowly absorbed. On the other hand, 
Losartan is a nonpeptide angiotensin II antagonist (Katwa et al., 1995; Ianello, 2006). 
Several reports have described the effects of ACE-inhibitors on myocardial infarction. Treatment 
with ACE inhibitors is known to cause reduction of left ventricular collagen content and to 
attenuate remodelling post myocardial infarct (consequently improving left ventricular function) 
(Ianello, 2006). 
1.7.1   Rationale for testing the effects of ACE-inhibitors on capsular contracture 
 
Angiotensin clearly has a role in organ fibrosis and in wound healing and there is significant 
evidence of the anti-fibrotic effect of ACE-Inhibitors. Previous laboratory work has consistently 
demonstrated a diminished fibrotic process in organs of animal models treated with ACE-Inhibitors 
or angiotensin II receptor antagonists (Yamagishi et al., 1996; Katwa et al. , 1997; Toblli et al., 
1999, 2004).   
ACE-Inhibitors such as enalapril are commonly used in renal and cardiovascular diseases and 
prevent the expression of fibrotic mediators. Such pharmacological therapy with ACE-Inhibitors 
has already been demonstrated to reduce capsular contraction on mammary implants in rat models. 
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Zinmann et al (2007), using a rat model, demonstrated that Enalapril lowered the expression of 
fibrotic mediators around mammary implants significantly reducing the inflammatory process and 
fibrosis.  Administration of AngII to skin wound models in rats also resulted in a reduction in 
healing times (McKirdy et al., 2003). Low dose ACE-inhibitors therapy has also been shown to 
improve post-operative cutaneous scarring in humans following abdominal surgery (Ianello, 2006). 
The present study aims to expand the findings of Zimman et al (2007) and McKirdy et al (2003) to 
establish whether the anti-inflammatory and anti-fibrotic ability of the renin-angiotensin system 
blockade, by an ACE-Inhibitor, can modulate the fibrotic process around mammary implants. This 
hypothesis may provide the basis for a safe and cheap therapeutic strategy with which to modify the 
capsular contracture that can affects women with mammary implants. 
 
1.8  Cell culture 
 
Cell culture, the technique to grow and maintain cells outside an organism or body, is practised 
extensively (Langdon, 2004). This technique is utilised for examination and manipulation of cell 
behaviour and to investigate fundamental processes of growth and development in both normal and 
abnormal including cell structure biochemical, genetic  and reproductive activity; metabolism, 
functions, and reactions to physical, chemical, and biological agents (such as drugs and viruses). 
 
There are two main types of cell culture: 
 Primary: derived from a living organism. 
 Cell lines: stable established cells which proliferate in culture. 
 
Both types of culture employ similar practical sterile techniques and in order to grow cells in 
culture, a variety of conditions must be met. A sample of the tissue is spread on or in a culture 
medium of biological (e.g., blood serum or tissue extract), synthetic, or mixed origin. The culture 
medium must have the appropriate nutrients, temperature, and pH specific to the cells being 
incubated. The results are observed with a microscope, sometimes after treatment (e.g., staining) to 
highlight particular features (Langdon, 2004). Research employing tissue culture techniques have 
helped to identify infections, enzyme deficiencies, and chromosomal abnormalities, classify brain 
tumours and formulate and test drugs and vaccines. The present study employed this tissue culture 
technique to grow myofibroblasts from breast capsules. 
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1.9  Immunohistochemistry 
 
Immunohistochemistry is the localisation of antigens or proteins in tissue sections by the use of 
labelled antibodies as specific reagents through antigen-antibody interactions that are visualized by 
a marker such as fluorescent dye, enzyme, or colloidal gold.  
 
1.9.1  Antibodies 
 
The pivotal reagent common to all immunohistochemical techniques is the antibody (Fig 1.8) 
(Kumar and Rudbeck, 1999). Antibodies belong to a group of proteins called immunoglobulins (Ig) 
that are present in the blood of immunised animals (Kumar and Rudbeck, 1999). The 
immunoglobulins comprise five major classes (in order of decreasing quantity found in plasma): 
IgG, IgA, IgM, IgD and IgE. Each is composed of two identical heavy chains and two identical 
light chains (Fig 1.8). IgG and IgM are the most utilised immunoglobulins for 
immunohistochemistry (Kumar and Rudbeck, 1999). 
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Fig 1.8. Schematic diagram showing the structure of an immunoglobulin molecule. It comprises 
two identical light chains and two identical  heavy chains held together by disulphide bonds (Taken 
from www.cas.vanderbilt.edu bsci111b/immunology/supplemental.htm). 
 
Polyclonal antibodies are a heterogeneous mixture of antibodies produced by different cells. They 
react with various epitopes of the antigen against which they are raised. The most frequently used 
animal for the production of polyclonal antibodies is the rabbit however they are also made in other 
mammals such as goats, pigs, guinea pigs and cows. The popularity of rabbits for this purpose is 
attributed to their ease of maintenance and relative rarity of human antibodies to rabbit proteins 
when compared to other mammals, such as goats (Boenisch, 1999; (Kumar and Rudbeck, 1999). 
 
Monoclonal antibodies are a homogeneous population of immunoglobulin as they are the product of 
an individual clone of plasma cells. Antibodies from a given clone are immunochemically identical 
and react with a specific epitope on the antigen against which they are raised (Kumar and Rudbeck, 
1999). Mice are the most commonly used animals for the production of monoclonal antibodies but 
may be produced in other species such as rat and camel (Harboe, 1983). 
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1.9.2  Direct Method 
 
Direct method is a single- step staining method. It utilizes a labelled antibody which directly reacts 
with the antigen in tissue sections. The advantage of this single-step method is that it is more time 
efficient however; it is limited by poor signal amplification with weak sensitivity and is rarely used 
since the introduction of the indirect method. 
 
1.9.3  Indirect Method: 
 
Indirect method is a two-stage process which involves an unlabelled primary antibody (first layer), 
which reacts with the tissue antigen, and a labelled secondary antibody (second layer) which then 
subsequently reacts with primary antibody. In order to do so, the secondary antibody must be 
against the IgG of the animal species in which the primary antibody was raised. This method is now 
preferred as it has a higher sensitivity due to signal amplification through several secondary 
antibody reactions with multiple antigenic sites on the primary antibody. Indirect 
immunofluorescence method is similar to method described however in addition; the second layer 
antibody is labeled with a fluorescent dye such as FITC, rhodamine or Texas red (Buchwalow and 
Bocker, 2010).  The present study used immunohistochemistry to identify the key receptors of the 
RAS, AT1 and AT2, in human breast capsule tissue. 
 
1.20  Gel Contractions 
 
Wound healing comprises of three processes: epithelialisation, connective tissue deposition, and 
contraction (Diegelmann, 2004). Tissue contraction is a dynamic event, believed to be mediated by 
myofibroblasts. There are several different culture models to study the ability of fibroblasts to 
reorganize and contract collagen matrices in vitro. Contraction models are produced from a 
polymerised collagen matrix containing cells. Mechanical tension develops during contraction, and 
cellular stress fibres assemble. This model allows the three dimensional cell matrix interactions and 
influence of specific agonists on the rate and extent of contraction to be investigated (Colgen, 
2006). In the floating contraction model, a freshly polymerized collagen matrix containing cells is 
released from the culture dish and allowed to float in culture medium, and contraction occurs in the 
absence of external mechanical load and without appearance of stress fibers in the cells. In the 
attached model, a polymerized collagen matrix containing cells remains attached to the culture dish 
during myofibroblast contraction. Mechanical tension then develops during contraction and cellular 
stress fibers assemble. Lastly, the two-step model of gel contraction combines an initial period of 
attached matrix contraction leading to mechanical loading, followed by release of the matrices, 
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resulting in mechanical unloading and further contraction as mechanical stress dissipates (Cell 
Biolabs, 2004). 
 
Three-dimensional collagen gels have been widely used in myofibroblast contraction studies and 
have also been used in the studies of integrin signalling, cell apoptosis and cytoskeleton 
reorganization. The collagen gel lattice contraction assay provides a model that takes advantage of 
the finding that cell- populated collagen-hydrogels contract over a period of time in a consistent 
manor (Colgen, 2006). The present study employed collagen gel contraction method to attempt to 
study the contractile behaviour of myofibroblasts from human breast capsule. 
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1.21                Working hypothesis 
 
Angiotensin receptors may be involved in the aetiology and development of capsular contracture 
disease. Identifying and blocking these receptors with ACE inhibitors may prevent fibrosis around 
mammary implants, providing a potential pharmacological treatment of this disease.  
 
1.22               Aims of Research 
 
Due to lack of treatment for this physically and psychologically debilitating complication which is 
common in women having breast reconstructive surgery, this project was designed to investigate the 
potential for pharmacological modulation of this disease. 
 
It has been proven in rodent models that: 
 There are increased levels of AngII or ACE during wound healing; 
 There is up-regulation of AT1 and AT2 receptors in wounded skin and; 
 Topical administration of AngII accelerates skin wound healing and an increased level of 
AngII or ACE.  (Liu et al., 2006). 
Therefore, the ‘Specific Aims’ of the study were: 
 To measure myofibroblast activity in vitro using tissue excised from surgery for capsular 
contracture disease. 
 To test the hypothesis that there is a local Renin-Angiotensin System in breast capsule 
around mammary implants. 
 To determine if AT1 or AT2 receptors are expressed in the fibrotic capsule around 
mammary implants. 
 The study also focuses whether the anti-inflammatory and anti-fibrotic ability of the Renin-
Angiotensin System blockade by an Angiotensin-Converting Enzyme (ACE) Inhibitor can 
modulate the fibrotic process around mammary implant tissue. 
 The study may provide the basis for a safe and cheap therapeutic strategy with which to 
modify capsular contracture affecting women with mammary implants. 
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Chapter II 
 
 
 
 
 
Materials and Methods 
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2.1. Reagents and Materials 
 
Patients: 
Twelve patients from Royal Preston Hospital 
 
Tissues:       
Isolated breast capsules from all 12 patients 
 
Reagents:   
Trypsin  
Collagenase Solution (2000 digestion units / ml): 
 500 mg Collagenase Type 1A 
 31.25 ml Hanks Balanced Salt Solution (HBSS) 
 
Antibodies:  
 Anti-AT1 receptor antibody produced in rabbit (AT1 (TONI-1): sc-67036 (Santa Cruz 
Biotechnology, INC, CA, USA)  
 Anti-AT2 receptor antibody produced in rabbit (AT2 (Anti-AGTR2: 53930904/ 1 in 4000 
dilution/ Sigma Aldrich, UK) 
 Anti-Actin, -Smooth Muscle antibody produced in mouse (αSMA (M0851/ 1 in 50 
dilution/ Dako, Cambridgeshire, UK) 
 
Cell Culture Media:  
DMEM, foetal calf serum, Ham’s F10 
 
Chemicals:   
Analar grade chemicals 
Dimethyl Sulfoxide (DMSO) 
 
Fixation and Immunohistochemistry:  
Tris Buffered Saline (TBS): 
 500 ml of distilled water 
 6.08 g Trizma Salt 
 4.6 g Sodium Chloride 
 0.5 g Bovine Serum Albumin 
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 Mixed well on a magnetic stirrer. PH of solution was corrected to approximately 7.4 using 
5M HCl 
 
Vectastain Universal Elite ABC Kit 
Normal blocking serum: 
 1 drop (50 l) of normal blocking serum stock added to 5 ml of Tris buffer pH 7.4 in mixing 
bottle. 
Biotinylated Secondary Antibody : 
 1 drop (50 l) of normal blocking serum added to 2.5 ml of Tris buffer pH 7.4 then one drop 
(50 l) of biotinylated antibody stock added to same bottle and mixed well. 
Vectastain Elite ABC Reagent: 
 1 drop (50 l) of Reagent A and 1 drop (50 l) of Reagent B added to 2.5 ml of Tris buffer 
pH 7.4 mixed immediately then allowed to stand for 30 minutes prior to use  
Diaminobenzidene Solution (DAB) 
 2.5 ml frozen stock solution 
 22.5 ml TBS 
 25 µl Hydrogen Peroxide 30% 
 
Collagen Gel Contraction: 
 Glacial acetic acid 99.9% 
 Sterile ELGA water 
 10 mg Collagen from Rat Tail (Sigma Aldrich C7661) 
 0.34M Sodium Hydroxide NaOH     
 Culture well plates (35 mm2) 
 22 µm syringe-driven filter units 
 200 µl pipette tips 
 Myofibroblasts 
 
Drugs:    
 Angiotensin II 
 Lisinopril  
 Penicillin  
 Streptomycin 
 Amphotericin 
 Glutamine  
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 [Val5]-Angiotensin II acetate salt hydrate  
 Irbesartan  
 S-(+)-PD 123177 trifluoroacetate salt hydrate 
 1-Methylhydantoin  
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2.1.1  Tissue Collection     
 
All experiments were approved by the National Ethics Service North West-8 Research Ethics 
Committee, Greater Manchester East (5
th
 October 2009. Study number: 09/H1013/58 (Appendix). 
The study was also approved by the Research and Development Ethics Committee, Lancashire 
Teaching Hospitals NHS Foundation Trust, Preston (1
st
 October 2009) (Appendix) and UCLAN. 
 
Female patients due to undergo treatment for capsular contracture disease, under the care of the 
Department of Plastic Surgery, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, 
were identified from the out-patient Plastic Surgery clinics and theatre Waiting-list Department. 
There were a total of 12 patients scheduled for this procedure during the research period. Patient 
information leaflets (appendix) were given to patients at least 24-hours prior to their operation and 
informed consent for tissue collection was obtained on the day of surgery (Appendix).  
Tissue samples of breast capsule from twelve unilateral breasts (in eight female patients) were 
collected intra-operatively under sterile conditions from the operating theatres. Specimens were 
transported in 15 ml test tubes (Fisher Scientific, Loughborough, Leicestershire, UK) containing 10 
ml Antibiotic Complete Growth Medium (100 ml of Complete Growth Medium [made from 500 ml 
of DMEM, 10 ml L-Glutamine solution and 50 ml Fetal Calf Serum] with 2 ml Penicillin and 
Streptomycin solution and, 1 ml of Amphotericin B solution).   
 
2.1.2   Tissue processing 
 
All experiments with human tissue were carried out under strict aseptic conditions within a laminar 
air flow hood (Holten HA2436BS, Fisher Scientific Inc, Loughborough, Leicestershire, UK) to 
maintain sterile conditions and avoid contamination. 
Excess subcutaneous fat was removed from the capsule specimens before cutting into 1 cm
2
 square 
pieces with a sterile blade.  Dissected specimen blocks from each breast capsule were then stored 
initially at 4⁰C in a 15 ml test tube containing 10 ml of Complete Growth Media (500 ml of 
DMEM, 10 ml L-Glutamine solution and 50 ml Fetal Calf Serum) for cell culture. In preparation for 
immunohistochemistry, portions from each specimen were also fixed using 4% paraformaldehyde 
in phosphate-buffered saline overnight. A portion of each fixed specimen was processed into 
paraffin blocks for histopathology. As staining was weak with paraffin sections, for patients 5-8, 
portions were also immediately placed into liquid nitrogen as frozen sections for 
immunohistochemistry.  
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2.1.3   Isolation of breast myofibroblasts 
 
The specimens for culture were stored in 10 ml Complete Growth Media at 4
o
C for 12-24 hours 
then transferred to a 100 X 15 mm Petri dish (BD Biosciences, Oxford, UK) containing 2 ml of 
Complete Growth Medium and dissected into small pieces using sterile forceps and scalpel prior to 
disaggregation. Dissected tissue was then transferred into a 15 ml centrifuge tube (VWR Inc, 
Lutterworth, Leicestershire, UK) containing 9 ml of Complete Growth Medium and 1 ml of 
Collagenase solution (2000 u/digestion Worthington Biochemicals, UK). The samples were 
incubated for 8-12 hours in a 5% carbon dioxide humidified incubator (Sanyo Biomedical, MCO - 
18AIC UV, Loughborough, Leicestershire, UK) at 37
o
C, agitating approximately every hour to 
promote disaggregation.   
 
Subsequently, preparations were pipetted several times to break down any large cell aggregates and 
the disaggregated cell suspensions centrifuged at 200 Xg  (Heraeus Megafuge 16R, Fisher 
Scientific, Loughborough, Leicestershire, UK)  for five minutes. The supernatant was carefully 
aspirated, leaving a small amount of medium above the pellet. The pellets were then re-suspended 
in 10 ml of Complete Growth Medium, centrifuged for a further five minutes at 200 Xg and the 
supernatant carefully aspirated above the dissociated cells. 
 
Thereafter, the dissociated cells were re-suspended in 2 ml of Complete Growth Medium and mixed 
well to achieve a homogenous, evenly distributed cell suspension. This was transferred into a 25 
cm
2
 cell culture flask (Fisher Scientific, Loughborough, Leicestershire, UK)  containing 8 ml of 
fresh Complete Growth Medium and incubated at 37
o
C in a humidified incubator with 5% CO2 
(Sanyo Biomedical, MCO - 18AIC UV, Loughborough, Leicestershire, UK). 
 
2.1.4   Cell line 
 
Foetal- lung fibroblast-like cell line (MRC-5, (PD 30) 05090501, Sigma, Aldrich, UK) was cultured 
as described in above in 10 ml of Complete Growth Media. 
The cell line was maintained in 25 cm
2 
initially, then 75 cm
2 
cell culture flasks in a 37⁰ C 
humidified incubator with 5% CO2 (Sanyo Biomedical, MCO - 18AIC UV, Loughborough, 
Leicestershire, UK).  For all experiments, the fibroblast cell line was used between passages two to 
four. 
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2.1.5   Subculture 
 
Culture flasks were kept in the incubator and sub-cultured when 70-80% confluent. For the third 
passage cells were transferred to a 75 cm
2
 culture flask.  
 
The spent medium was aspirated from the culture flask and the flask washed with HBSS (2 ml for 
25 cm
2 
flask and 5 ml for 75 cm
2 
flask). The media were then removed and 0.25% trypsin (Lonza, 
Slough, Berkshire, UK) was added to the culture flask (1 ml for 25 cm
2 
flask and 2 ml for 75 cm
2 
flask) which was subsequently incubated at 37⁰C for five minutes. 
 
Next, the culture flasks were gently tapped and viewed under the inverted light microscope 
(Olympus IMT-2) to ensure cells were adequately detached. The culture flasks were then sprayed 
with alcohol, wiped down and returned to the laminar flow hood (HA2436BS, Fisher Scientific Inc, 
Loughborough, Leicestershire, UK).  A volume of 2 ml of Complete Growth Medium was added to 
neutralize the trypsin reaction and prevent unwarranted damage to cell membranes caused by 
trypsin exposure. The cell suspension was then pipetted several times to separate any remaining cell 
aggregates and transferred to a 15 ml centrifuge tube (Fisher Scientific, Loughborough, Leicester, 
UK).  
 
The cell suspension was centrifuged at 200 Xg (Heraeus Megafuge 16R, Fisher Scientific, 
Loughborough, Leicestershire, UK) for five minutes and the supernatant was carefully aspirated, 
leaving a small amount of medium above the pellet. The pellet was then re-suspended in 2 ml of 
Complete Growth Medium and mixed well. This cell suspension was then added to new flasks 
containing 10 ml of Complete Growth Medium for re-culture and returned to the incubator at 37⁰C.  
 
Cell cultures were examined twice a week and the media containing unattached cells was aspirated 
and fresh Complete Growth Medium added. Cells from subsequent passages three to five were used 
for all experiments. 
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2.1.6   Cell counting 
 
Once cells were trypsinized, 50 µl of cell suspension was pipetted into a sterile Eppendorf tube for 
cell-counting. A volume of 50 µl of Trypan Blue (Sigma, Aldrich, UK) was added to help 
distinguish live cells as this stain is only taken up by viable cells. Cover slips were attached onto the 
slide over the chambers of a Neubauer Haemocytometer. Approximately 20 µl of the cell and 
Trypan Blue suspension was pipetted out onto the haemocytometer and viewed under an inverted 
light microscope. The number of cells in 25 squares of one chamber was counted, and then the 
process repeated for the remaining chambers. The average number of cells in the centre grid was 
counted and this number multiplied by 2 x 10
4 
to obtain the number of cells per 1 ml of cell 
suspension.  
 
Cells were also counted using a Coulter- Counter (Beckman Coulter, High Wycombe, 
Buckinghamshire, UK) method. The Coulter Counter was flushed using Isoton II diluent. The 
particle size was set to 10 µm and a background count was performed initially using diluent only.  
A volume of 100 µl of cell suspension was then pipetted into an Accuvette II vial (Beckman 
Coulter, High Wycombe, Buckinghamshire, UK) and, 10 ml of Isoton II diluent was added. Each 
suspension was counted three times and an average cell count was calculated. 
 
2.1.7   Cell freezing 
 
Cells were passaged as previously described and harvested at 80-90% confluence. Cells were then 
counted as described. 
 
The cells were centrifuged at 200 Xg  for five minutes and the cell pellets re-suspended in the cell 
freezing media consisting of a ratio 90% media to 10% (v/v) of the cryoprecipitant Dimethyl 
Sulfoxide, (DMSO, Sigma, Aldrich, UK) to give a final cell concentration of 1 X 10
6
cells per ml. 
 
A volume of   1 ml of the cell suspension was aliquoted into cryovials (Greiner Bio One, 
Stonehouse, Gloucestershire, UK) and frozen at a cooling rate between 1-3⁰C/min using a 
programmable rate controlled freezer to prevent damage to the cells. The cells were kept in the 
freezer and once at -130⁰C the ampoules were transferred to a gas phase liquid nitrogen storage 
vessel the next day. 
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2.1.8   Culturing cells from frozen cryovials 
 
For culturing cells from frozen cryovials, the respective media (10 ml Complete Growth Media was 
pre-warmed in a water bath to 37⁰ C. The cryovials were removed from the liquid nitrogen and 
immediately immersed into the water bath at 37⁰C. Once de-frosted, the vials were wiped clean and 
sprayed with alcohol prior to the cells being cultured in a 75 cm
2 
flask containing 10 ml of the pre-
warmed fresh Complete Growth Media. The flasks were incubated overnight at 37⁰C then the 
media changed to remove any residual cryoprecipitant (DMSO).  
 
2.2    Light Microscopy and Immunolabelling 
 
2.2.1  Staining of primary cells 
 
Myofibroblasts were trypsinized and 10
3 
cell suspension was pipetted into six-well culture chamber 
slides (BD Falcon, BD Biosciences, Oxford, UK) and grown in Complete Growth Medium to 50-
60% confluence.  The medium was aspirated from the chambers and the monolayers were washed 
three times with TBS. 
 
Cells were then covered with a 1:1 ratio of methanol: acetone (pre-chilled to –20oC) and placed 
rapidly into a –20oC freezer for 10 minutes to fix. Next, fixative was removed from the chambers 
and the cells allowed to air dry. Cells were stored in a –20oC freezer prior to immunostaining. 
 
Immunolabelling of specimens was carried out by a modified avidin-biotin-peroxidase complex 
technique (Vectastain ABC kit; Universal Elite, Vector Laboratories, Calif). Firstly, cells were 
rehydrated with three washes of Tris Buffered Saline (TBS) before the administration of the 
primary antibody. For AT1 receptor studies an AT1 receptor antibody was used (TONI-1: 67036/ 1 
in 40 dilution/ Santa Cruz Biotechnology, INC, CA, USA). For AT2 receptor studies an AT2 
receptor antibody was used (Anti-AGTR2: 53930904/ 1 in 4000 dilution/ Sigma Aldrich, UK).  
 
A volume of 100 µl of primary antibody was pipetted into each chamber and the cells incubated 
with the lid replaced for 30, 60, 90 minutes and 12 hours respectively at room temperature. For each 
experiment, the primary antibody was omitted from one sequence for each specimen as a control 
study. Cells were then rinsed three times with TBS. Thereafter, the cells were incubated in 100 µl of 
the secondary antibody with the lid replaced for a further 30 minutes at room temperature. After 30 
minutes any excess antibody was removed and the cells rinsed with three washes of TBS. A volume 
of 100 µl of ABC Reagent was subsequently pipetted into each chamber and cells incubated with 
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the lid replaced for a further 30 minutes at room temperature. Excess solution was removed and 
cells washed three times with TBS. 
 
Diaminobenzidene (DAB) solution was mixed immediately prior to adding to each chamber using 
0.1% diaminobenzydine (Peroxidase Substrate Kit (DAB) SK-4100; Vector Laboratories, Calif) and 
0.2% hydrogen peroxide in 50 mM Tris buffer, pH 7.5.  The cells were exposed to the DAB 
solution for five minutes then any excess was removed and the cells rinsed three times with distilled 
water. 
 
Chamber slides (BD Falcon, BD Biosciences, Oxford, UK) were then counterstained by pipetting 
haematoxylin into each chamber for 15 seconds then rinsed several times with warm tap water to 
stain the nuclei. Cells were dehydrated by passing the chambered slides serially from water through 
graded concentrations of alcohol (50% ethanol, 70% ethanol, 90% ethanol and 100% alcohol). After 
rinsing, the chambered sections were removed from the slide and mounted in styrolite using a large 
cover slip. 
 
Uptake was visualised by confocal microscopy and images captured with a 3.2 megapixel digital 
camera. 
 
2.2.2   Staining of paraffin and frozen sections 
 
Paraffin sections were de-waxed in xylene. Sections were then taken through decreasing 
concentrations of alcohol to water (100% alcohol, 90% ethanol, 70% ethanol, 50% ethanol then 
water). The microwave method, as first described by Shi et al. (1991) , was used for high 
temperature antigen unmasking. The sections were then rehydrated with three washes of phosphate-
buffered saline.  
 
Frozen sections were allowed to de-frost overnight at room temperature. Sections (5–7 µm) of 
breast capsule, cut using a microtome (Rotary Microtome HM 325, Fisher Scientific, 
Loughborough, Leicester, UK) were then air dried onto glass slides (Surgipath X-tra Adhesive, 
Leica Biosystems, Newcastle Upon Tyne, UK). 
 
Slides were then washed in running tap water then rinsed with TBS prior to placing on an 
immunostaining tray. Any excess moisture was carefully dried.  Quenching of endogenous 
peroxidase activity was achieved by incubating the sections in Dako hydrogen peroxide blocking 
reagent for five minutes, with the lid replaced, at room temperature.  The sections were then washed 
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three times with TBS and any excess moisture dried. The sections were then incubated with normal 
blocking serum for 20 minutes with the lid replaced.  
 
Without washing, next the 100 µl of primary antibody was added: AT1 receptor antibody (TONI-1: 
67036/ 1 in 40 dilution/ Santa Cruz Biotechnology, INC, CA, USA) and AT2 receptor antibody 
(Anti-AGTR2, 53930904/ 1 in 4000 dilution/ Sigma Aldrich, UK). Kidney paraffin sections were 
used as a control for AT1 and AT2 receptor antibody staining. Smooth Muscle Actin was also 
quantified using monoclonal mouse anti human smooth muscle actin (M0851/ 1 in 50 dilution/ 
Dako, Cambridgeshire, UK).  Small bowel paraffin sections were used for α-sma staining controls. 
For each experiment, the primary antibody was omitted from one sequence for each specimen as a 
control study. 
 
Sections were then rinsed three times with TBS prior to incubation with the secondary antibody. 
100 µl of secondary antibody was added to each slide using a pipette and incubated, with the lid 
replaced, for a further 30 minutes at room temperature. After three washes in TBS the sections were 
then incubated for 30 minutes with Vectastain Elite ABC reagent (Universal Elite, Vector 
Laboratories, Calif). A volume of 100 µl of streptABComplex/HRP solution was then added to each 
slide using a pipette. Slides were then incubated, with the lid replaced, for 30 minutes at room 
temperature. Excess solution was removed and slides washed three times with TBS and then 
exposed for five minutes to 0.1% diaminobenzydine (Peroxidase Substrate Kit (DAB) SK-4100; 
Vector Laboratories) and 0.2% hydrogen peroxide in 50 mM Tris buffer, pH 7.5 (mixed and used 
immediately). After five minutes excess DAB was removed and the slides rinsed three times with 
distilled water. 
 
The slides were counterstained in haematoxylin and washed in hot running water until blue. 
Following this they were dehydrated in alcohol then taken through to xylene. Slides were mounted 
in styrolite and viewed using a Digital Microscope (Coolscope- Nikon, Kingston Upon Thames, 
Surrey, UK) to visualise the distribution of immunoreactivity and capture the images for analysis. 
Slides were also viewed by an independent histopathologist regarding distribution of 
immunoreactivity to exclude bias. 
 
 
 
 
 
 
50 
 
2.3  Gel contraction  
 
Based on method described by Colgen (2006). 
 
2.3.1  Preparation of collagen 
 
Acetic acid solution (0.2 %) was prepared from 99.9 % glacial acetic acid and water. The solution 
was sterilised by passing through the syringe-driven filter units and then cooled to 4⁰ C. Rat tail 
collagen (Sigma Aldich, UK) was mixed with the 0.2 % acetic acid solution under sterile conditions 
to a concentration of 6 mg/ ml. The solution was mixed on a magnetic stirrer (Fisher Scientific, 
Loughborough, Leicestershire, UK) for two- five days in a refrigerator at 4⁰C until the collagen was 
completely dissolved in solution. The collagen solution was then diluted to a concentration of 3 mg/ 
ml and 0.1 % acetic acid with sterilized water, stirred for a further 24 hours and subsequently stored 
at 4⁰C. 
 
2.3.2  pH (NaOH) titration of collagen 
 
A volume of 0.4 ml of Dulbecco’s Modified Eagle’s Medium was pipetted into eight individual 
Eppendorf tubes. Next, 0.2 µl of the prepared 3 mg/ ml collagen solution and 1 µl of 1M NaOH 
were added to the first Eppendorf tube and the solution pipetted up and down to produce a collagen 
concentration of 1 mg/ ml. This process was repeated with increasing concentrations (2-10 µl) of 
NaOH. The viscosity and colour of the gels were compared to determine the optimal volume of 
NaOH to produce a viscous gel with a neutral pH. 
 
2.3.3   Preparation of cells for gel contraction 
 
Myofibroblasts were trypsinized and centrifuged at 200 Xg for five minutes (Heraeus Megafuge 
16R, Fisher Scientific, Loughborough, Leicestershire, UK). Once cells were trypsinized, 50 µl of 
cell suspension was pippeted into a sterile Eppendorf for cell-counting. The supernatant was 
aspirated and the cells re-suspended in Complete Growth Media. Cells were then counted using a 
Coulter-Counter (Beckman Coulter, High Wycombe, Buckinghamshire, UK). The remaining 
suspension was re-centrifuged at 200 Xg for five minutes and fresh Complete Growth Media (+/- 
experimental variable) was added to achieve a homogenous concentration of 1.5 x 10
5 
cells per ml 
following the addition of the collagen solution. 
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Collagen gels were prepared under sterile conditions. A volume of 0.66 ml of cell suspension (+/- 
experimental variable) was added to a sterile 10 ml test tube. A volume of 0.33 ml of collagen 
solution (1 mg/ ml) was added to the test tube followed immediately by the optimal volume of 
NaOH. The solution was pipetted to mix thoroughly then transferred to a 35 mm
2 
culture well plate 
(BD Biosciences, UK) and allowed to set overnight at 37⁰C.  
 
To investigate the RAS agonists and antagonists on the rate of gel contraction the following 
experimental variables were studied: 
 
 [VAL5]-Angiotensin II acetate salt hydrate (AT1 receptor agonist- A2900 Sigma Aldrich) 
 Irbesartan (AT1 antagonist- 12286 Sigma Aldrich) 
 S-(+)-PD123177 trifluroacetatesalt hydrate (Selective AT2 receptor antagonist- P5749 
Sigma Aldrich) 
 1-methylhydantoin (AT2 receptor agonist M49887 Aldrich) 
 Lisinopril (ACE- inhibitor- L2777 Sigma Aldrich) 
 
Four of the wells were treated with different concentrations 5, 10, 20 and 40 µl/ml of the variable, a 
fifth was treated with 20 µl/ml of the respective antagonist and the sixth well was left untreated 
(control). Contraction rates were measured using a standard ruler for several days afterwards.  
Images were captured at 24, 48, 72 and 96 hours respectively. 
 
2.4  Statistical analysis of data 
 
All experiments were repeated at least three times to ensure that the experimental results were 
consistent and reliable. Histopathology slides were also reviewed by an independent 
Histopathologist to exclude bias. Values are presented as means ± SE. Statistical differences 
between the data were evaluated by the Student’s t-test, with P < 0.05 used as the requirement for 
significance. All analyses used the conventional two-sided 5% significance-level and were 
produced using Self- Propelled Semi-Submersible (SPSS) Version 15.  
 
 
 
 
 
52 
 
 
 
 
 
 
Chapter III 
 
 
 
 
 
Results 
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Study 1 
 
3.1   Studies into patient population with capsular contracture disease 
 
3.1.1   Patient demographics and co-morbidities 
 
All patients in the study were female, undergoing surgical treatment for capsular contracture 
disease. Four patients (50%) had bilateral breast capsule surgery and four patients (50%) underwent 
unilateral procedures. Therefore, tissue samples of breast capsule from a total of twelve single 
breasts in eight study patients were harvested.  All patients were treated under the care of the 
Department of Plastic Surgery, Lancashire Teaching Hospitals NHS Trust, Preston, between 
October 2010 and March 2011. Mean patient age was 48.8 years (range 22- 65 years ± 12.95). 
Mean patient body mass index (BMI) was 26.4 (range 22 - 30.5 ± 2.72). The average duration of 
breast implants was 51.5 months (range 6 - 120 months ± 38.2). 
Co-morbidities amongst the study population included none (n=2, 25%), asthma (n=1, 12.5%), 
hypertension (n=2, 25%), reflex sympathetic dystrophy (n=1, 12.5), osteoarthritis (n=2, 25%), 
hypercholesterolemia (n=2, 25%) and hypothyroidism (n=1, 12.5%). Three patients in the study 
(37.5%) had previously undergone surgical treatment and adjuvant radiotherapy for breast cancer. 
None of the patients had active breast cancer at time of treatment for capsular contracture and tissue 
harvest. Other previous surgical procedures included none (n=3, 37.5%) cholecystectomy (n=2, 
25%), appendicetomy (n=1, 12) caesarean section (n=2, 25%), laparoscopic gastric bypass for 
obesity (n=1, 12.5%), post bariatric abdominoplasty (n=1, 12.5%), total abdominal hysterectomy 
and bilateral salpingoophorectomy (n=1, 12.5%). Three patients in the study were smokers (37.5%).   
Regular medications taken by the patients in the study were of the drug classes  beta-blockers (n=2, 
25%), beta-2 adrenergic receptor agonist inhalers (n=1,  12.5%), anti-depressants (n=1,  12.5%), 
proton-pump inhibitors (n=1,  12.5%), diuretics (n=1,  12.5%), statins (n=2, 25%), anticonvulsants 
(n=1,  12.5%), thyroid hormones (n=1,  12.5%),  and oestrogen-receptor antagonists (n=2, 25%).  
Three patients did not take any regular medications (37.5%).  Interestingly, none of the patients in 
the study took ACE-inhibitors. 
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Table  3.1: Patient demographics and co-morbidities: age; body mass index (BMI); past medical 
history; past surgical history; smoking status and drug history. 
 
 
 
 
 
Patient Age BMI Past Medical History Past Surgical History Smoking 
Status 
Drug History 
1 
 
41 26.5 Asthma 
 
Cholecystectomy 
 
Smoker Salbutamol inhaler 
 
Citalopram 
 
 
2 49 28 Hypertension 
 
Reflex sympathetic 
dystrophy 
 
 
Laparoscopic gastric 
bypass 
 
Post- bariatric-
abdominoplasty 
 
Caesarean section 
 
Non-
smoker 
 
Lansoprazole 
 
Bendroflumethiazide 
 
Gabapentin 
3 
 
55 27 Fit and well 
 
Nil Non-
smoker 
No regular 
medications 
4 
 
49 30.5 Grade II invasive ductal 
carcinoma right breast 
 
Hypercholesterolemia 
 
Nil Non-
smoker 
Tamoxifen 
 
Simvastatin 
 
5 
 
65 27 Osteoarthritis 
 
 
Cholecystectomy 
 
Total abdominal 
hysterectomy and 
bilateral 
salpingoophorectomy 
 
Non-
smoker 
No regular 
medications 
6 
 
52 22 Grade II invasive ductal 
carcinoma left breast 
with ductal carcinoma 
in situ 
 
Hypothyroidism 
Nil Smoker Levothyroxine 
7 22 26.5 Fit and well 
 
Appendicetomy 
 
Non-
smoker 
 
No regular 
medications 
8 
 
58 23.5 Grade III invasive 
ductal carcinoma right 
breast 
 
Osteoarthritis 
 
Hypercholesterolemia 
Hypertension 
 
Caesarean section Smoker Tamoxifen 
 
Bisoprolol 
 
Simvastatin 
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Figure 3.1: Bar chart showing the distribution of age of the study population. Mean age was 48.8 
years (range 22 – 65 years ± 12.95).  
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3.1.2  Indications for initial breast augmentation 
 
Indications for initial breast implant placement included breast reconstruction following breast 
cancer (n=3, 37.5%); correction of asymmetry following multiple lumpectomies for benign breast 
disease (n=1, 12.5%); correction of congenital asymmetry (n=1, 12.5%); augmentation post 
bariatric weight loss (n=1, 12.5%); and breast augmentation for cosmesis (n=2, 25%). 
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Figure 3.2: Pie chart showing the indications for initial breast augmentation amongst the study 
population.  
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3.1.3  Baker Grade of capsular contracture 
 
Regarding the degree of capsular contracture (Baker’s classification) surgical interventions were 
performed for Baker Grade III and IV capsular contractures only in the study population (Grade I 
and II do not routinely require surgical excision unless symptomatic). Capsule samples were 
harvested from 12 breasts in the eight study patients. Seven (58%) implants had grade IV capsular 
contractures and, five (42%) implants had grade III capsular contractures. 
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Figure 3.3: Pie chart showing the Baker classification of severity of capsular contracture amongst 
the study population. (Grade I: breast is normally soft and looks natural; Grade II: breast is a little 
firm but looks normal; Grade III: breast is firm and looks abnormal; Grade IV: breast is hard, 
painful, and looks abnormal). 
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Table 3.2: Table showing the breast laterality of capsule specimens, indications for initial 
augmentation and, Baker Grade of capsular contracture for the study population. 
 
Patient Capsule 
Laterality 
Specimen  Indication Baker 
Grade 
1  Left 
Breast 
A Bilateral breast augmentation for 
cosmesis 
 
III 
2  Left 
Breast 
B Bilateral breast augmentation post 
bariatric 
 
IV 
Right 
Breast 
C III 
3  Left 
Breast 
D Bilateral breast augmentation for 
cosmesis 
III 
Right 
Breast 
E IV 
4  Left 
Breast 
F Reconstruction following wide local 
excision and radiotherapy for breast 
cancer right breast 
III 
Right 
Breast 
G IV 
5  Right 
Breast 
H Reconstruction following multiple 
lumpectomies for benign breast disease 
IV 
6  Left 
Breast 
I Reconstruction following surgery and 
radiotherapy for breast cancer left 
breast 
 
IV 
Right 
Breast 
J III 
7  Left 
Breast 
K Bilateral breast augmentation for 
congenital asymmetry 
IV 
8  Right 
Breast 
L Reconstruction following mastectomy 
and radiotherapy for breast cancer right 
breast 
IV 
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The aetiological factors contributing to capsular contracture disease amongst the study group were 
recorded. Capsular contracture is recognised to have a higher incidence and, also be more severe, in 
women who undergo breast reconstruction following surgery for breast cancer (Handel et al, 1995). 
Three patients in the study initially had breast reconstruction following breast cancer and 
radiotherapy. They all developed more severe, Baker Grade IV, capsular contractures. 
 
3.1.4   Previous surgical treatments for capsular contracture disease 
 
Mean number of previous surgical interventions for capsular contracture was 2.75 procedures 
(range 1 – 9 ± 3.37). The results demonstrate the challenges associated with treatment of capsular 
contracture which often re-occurs despite surgical excision. Patient three was particularly prone to 
forming capsular contracture of her right breast (Specimen E). She had undergone six previous 
surgical procedures for treatment of recurrent capsular contracture disease prior to the study.  
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Figure 3.4: Bar chart showing the number of previous surgical interventions for treatment of 
capsular contracture disease. 
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3.1. 5  Risk factors for capsular contracture disease 
 
Risk factors for forming capsular contracture amongst the study patients included radiotherapy 
(n=3, 37.5%), post-operative haematoma (n=2, 25%), implant infection (n=2, 25%), implant rupture 
with silicone leakage (n=1, 12.5%) and smoking (n=3, 37.5%). 
 
The results demonstrate that the aetiological factors thought to play a role in the formation of 
capsular contracture including radiotherapy, haematoma, infection, silicone leakage and smoking 
were all common findings amongst the study group, thus supporting these theories. 
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Figure 3.5: Bar chart showing the risk factors for capsular contracture disease amongst the study 
population. 
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Section 3.1.6  Surgical intervention performed for capsular contracture treatment 
 
All operations were performed by a Plastic Surgery Consultant or a Senior Specialist Registrar in 
Plastic Surgery, under the supervision of the Consultant. Four patients (50%) had bilateral breast 
capsule surgery and four patients (50%) underwent unilateral procedures for the treatment of 
capsular contracture disease at the time of tissue harvest. Surgical interventions performed included 
capsulectomy (n=10 breasts, 83%) or capsulotomy (n=2 breasts, 17%).  
 
All procedures were performed under general anaesthesia. Mean length of patient hospital stay 
following surgery for capsular contracture was 2.85 days (range one- five days ± 1.25). Prolonged 
hospital stay (four or more days) was either due to post- operative complications including 
haematoma (n=1, 12.5%) or excessive output from suction drains (n=2, 25%). 
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Figure 3.6: Bar chart showing the type of surgical intervention performed for treatment of capsular 
contracture disease at tissue harvest (i.e. capsulotomy or capsulectomy). 
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3.1.7   Breast implant analysis 
 
Of the 12 breast implants removed at the time of surgical treatment for capsular contracture and 
tissue harvest 11 were silicone filled (92%) and only one implant (8%) (patient 7, specimen K) was 
saline filled.  Mean implant volume (size) was 300 cubic centimetres (cc), (range 255-330cc).   
 
Ten (83%) of the implants removed were smooth and only two (17%) had a textured surface 
(patient 3). 11 implants (91%) were intact with no evidence of silicone leakage. One implant (8%) 
demonstrated gel bleed (separation of small molecules of silicone from the surface of the implant) 
which is an indicator of implant degeneration (patient 6, specimen G).  
 
The numbers of saline filled implants, and those with smooth textured surfaces were too small to 
assess whther implant filler type or surface typer were associated with severity of capsular 
contarcture. 
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Figure 3.7: Pie chart showing the type of implant filler material of the mammary prostheses 
removed from the study population at the time of surgery. 
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Figure 3.8: Pie chart showing the type of implant surface of the mammary prostheses removed 
from the study population at the time of surgery. 
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Study 2 
 
3.2      Studies into breast capsule myofibroblasts 
 
3.2.1 Cell culture: growth curves of human breast capsule myofibroblasts 
 
Myofibroblasts from breast capsule tissue were successfully isolated and grown in culture. 
Growth curves of the primary human breast myofibroblasts were constructed to show the total 
number of cells at different time points. Cells were counted as described in section 2.1.6. 
 
 
 
Figure 3.9: Time course growth curves demonstrating total number of human breast myofibroblasts 
(Specimens D and I) over a period of ten days in subculture. The cells reached the peak of growth 
after 7.5 days. Cells reached a confluent level at 8.5 days, after which, the total cell number began 
to decrease as there was limited growing space due to cell density. There were no significant 
differences between the cultures. Data are the mean of three cultures.  
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Study 3 
 
3.3      Studies into fibroblast cell line 
 
3.3.1 Cell culture. Growth curves of foetal lung fibroblasts 
 
Growth curves of the foetal lung fibroblasts were constructed to show the total number of cells at 
different time points. Cells were counted as described in section 2.1.6. 
 
 
 
Figure 3.10: Time course growth curves demonstrating total number of foetal-lung fibroblast-like 
cells (MRC-5, (PD 30) 05090501, Sigma, Aldrich, UK) over a period of seven days in subculture. 
The cells reached the peak of growth after five days. Cells reached a confluent level at 5.5 days, 
after which, the total cell number began to decrease as there was limited growing space due to cell 
density. Data are the mean of three cultures.  
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Study 4 
 
3.4      Studies into breast capsule architecture: immunohistochemistry 
 
3.4.1    Haematoxylin and Eosin staining of tissues  
 
All breast capsules consisted of dense fibrous tissue with chronic inflammatory infiltrates. There 
was evidence of contributing factors to the formation of capsular contracture in specimen G with 
foreign body giant cell reaction secondary to leaked implant material. The results of these capsule 
architectural studies suggest that tissue injury caused by the implant produces inflammatory 
mediator activation, enhancing the fibrotic process therefore increasing collagen matrix and the 
number of inflammatory cells. 
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Figure 3.11: Micrograph showing haematoxylin & eosin staining of human breast capsule, 
Specimen A (100 x magnification) demonstrating breast tissue with surrounding fibrosis at the 
capsule-breast tissue interface (breast duct centrally surrounded by two breast lobules). This is 
typical of three different experiments on similar tissues (n=3). 
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Figure 3.12: Micrograph showing haematoxylin & eosin staining of human breast capsule, 
Specimen G (100 x magnification). This section of dense fibrous breast capsule contains patchy 
chronic inflammatory cells, including histiocytes, which can be seen surrounding leaked foreign 
implant material (secondary to previous ruptured implant), in an attempt to remove it by 
phagocytosis. There is also foreign body giant cell reaction secondary to the leaked implant 
material. This chronic irritation and inflammation is thought to be a causative factor in the 
formation of capsular contracture. This is typical of three different experiments on similar tissues 
(n=3). 
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Figure 3.13: Micrograph showing haematoxylin & eosin staining of human breast capsule, 
Specimen H (100 x magnification). There is a thick fibrous hyaline breast capsule with focal 
calcium deposits suggesting a chronic inflammatory process. This is typical of three different 
experiments on similar tissues (n=3). 
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Figure 3.14:  Micrograph showing haematoxylin & eosin staining of human breast capsule, 
Specimen I (100 x magnification) demonstrating a dense fibrous breast capsule. The elongated 
fibroblast cells produce collagen which has contracted to produce this uniformly dense mature 
fibrous scar tissue. This is typical of three different experiments on similar tissues (n=3). 
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3.4.2  Morphological characteristics of primary breast capsule myofibroblasts 
 
As depicted below, the myofibroblast cells in breast capsule tissue were large and flat, with 
elongated processes protruding from the body of each cell, creating a spindle-like appearance. The 
nuclei in the body of the cells were oval. These cells can resemble normal fibroblasts however, 
immunostaining for -SMA was subsequently performed to confirm that the cells were in fact 
myofibroblasts. 
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Figure 3.15: Light micrograph showing Specimen A, passage four. Subculture of human breast 
capsule myofibroblasts with cytoplasmic branches and elliptical speckled nuclei (100 x 
magnification). These active myofibroblasts forming collagen have abundant rough endoplasmic 
reticulum (RER). This image is typical of the appearances of the myofibroblasts in five different 
experiments on similar tissues (n=5). 
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Figure 3.16: Light micrograph showing Specimen F passage five. Subculture of human breast 
capsule myofibroblasts with fusiform morphology (100 x magnification). This image is typical of 
the appearances of the myofibroblasts in five different experiments on similar tissues (n=5). 
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Study 5 
 
3.5   Angiotensin-II Type-1 receptor studies 
 
3.5.1  Immunostaining of primary myofibroblasts  
 
There was no uptake of Angiotensin Type 1 (AT1) receptor antibodies in the primary cultured 
human breast capsule myofibroblast smears.  
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Figure 3.17: Micrograph showing breast capsule myofibroblast smear, Specimen A passage 5. AT1 
1 in 40 (100 x magnification). No immunopositivity within the myofibroblast cells. Note the 
elongated projections of the myofibroblast cells. The negative control was also negative for 
immunostaining. This image is typical of 15 different experiments on similar tissues (n=15). 
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3.5.2  Immunostaining of paraffin sections 
 
 
 
 
 
 
 
 
Figure 3.18: Micrograph showing paraffin section specimen G. AT1 1 in 40. Fibroblasts within this 
dense collagenous capsule show no staining. This image is typical of 15 different experiments on 
similar tissues (n=15). 
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Figure 3.19:  Micrograph showing paraffin section, Specimen H. AT1 1 in 40 (10 x magnification) 
demonstrating weak staining within the vessel walls but also weak uptake within the stromal 
spindle myofibroblast cells. This image is typical of 12 different experiments on similar tissues 
(n=12). 
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Although AT1 and AT2 detection was low in the paraffin sections using polyclonal anti-AT1R 
antibodies, this may have been because of the tissue fixation method used and/or a low detection 
efficiency. Similarly, lack of uptake in the fibroblast culture smears potentially due to an antigen 
retrieval deficiency limitation. 
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3.5.3              Immunostaining of cryostat sections 
 
 
 
 
 
Figure 3.20: Micrograph to show frozen section of Specimen L. AT1 1 in 40 (20 x magnification). 
No immunopositivity is seen. Although AT1 and AT2 detection was low in the paraffin sections 
using polyclonal anti-AT1R antibodies, this may have been because of the tissue fixation method 
used and/or a low detection efficiency. Similarly, lack of immunostaining in the fibroblast culture 
smears potentially due to an antigen retrieval deficiency limitation. This image is typical of 12 
different experiments on similar tissues (n=12). 
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Figure 3.21: Micrograph showing frozen section of Specimen I. AT1 1 in 40 (10 x magnification). 
Although there is a slight background staining, the weakly positive stromal myofibroblast cells are 
evident in this section. This image is typical of 12 different experiments on similar tissues (n=12). 
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Figure 3.22: Micrograph showing frozen section of Specimen J: AT1 1 in 40 (100 x 
magnification). Immunopositivity is seen in the stromal myofibroblasts and the cells of the 
synovial-like metaplasia of the breast capsule. This image is typical of 12 different experiments on 
similar tissues (n=12). 
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3.5.4   Control 
 
In the kidney controls, for all experiments, AT1 and AT2 receptor staining uptake were positive in 
the endothelial cells of vessels including interlobular arteries, afferent and efferent arterioles, and 
glomerular capillaries, as previously reported (Tsutsumi et al, 1998).  
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Figure 3.23: Micrograph showing the kidney control. AT1 1 in 40 (50 x magnification). There is 
positive staining for the AT1 antibody in the cells lining the tubules. This image is typical of 12 
different experiments on similar tissues (n=12). 
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Study 6 
 
3.6  Angiotensin-II Type-2 receptor studies 
 
3.6.1  Immunostaining of primary myofibroblasts  
 
There was no uptake of Angiotensin II- Type 2 (AT2) receptor antibodies in the primary cultured 
human breast capsule myofibroblast smears. This may be due to ineffective antigen retrieval or low 
levels of expression. 
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Figure 3.24: Micrograph showing breast capsule myofibroblast smear of Specimen B passage five, 
AT2 1 in 4000 (40 x magnification). No immunostaining is seen within the elongated myofibroblast 
cells. This image is typical of 15 different experiments on similar tissues (n=15). 
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3.6.2  Immunostaining of paraffin sections 
 
 
 
 
 
 
 
Figure 3.25: Micrograph showing paraffin section of Specimen B. AT2 1 in 4000 (2 x 
magnification) No immunostaining is noted in the myofibroblasts. This section demonstrates the 
architecture of a dense mature fibrous capsule. This image is typical of 12 different experiments on 
similar tissues (n=12). 
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3.6.3  Immunostaining of cryostat sections 
 
 
 
 
 
 
 
Figure 3.26: Micrograph showing frozen of Section Specimen H. AT2 1 in 4000. Strong 
immunopositivity is seen in the stromal spindle fibroblasts; the blood vessel walls provide an inbuilt 
internal control. This image is typical of 12 different experiments on similar tissues (n=12). 
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Figure 3.27: Micrograph showing frozen Section of Specimen I. AT2 1 in 4000 (10 x 
magnification) demonstrating strong immunopositivity within smooth muscle walls and spindle-cell 
shaped myofibroblast cells. This image is typical of 12 different experiments on similar tissues 
(n=12). 
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Figure 3.28: Micrograph showing frozen Section of Specimen J: AT2 1 in 4000 (50 x 
magnification). The stromal myofibroblasts in this section show strong immunopositivity. The 
blood vessels again provide an internal positive control for the stain. This image is typical of 12 
different experiments on similar tissues (n=12). 
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Figure 3.29: Micrograph showing frozen Section of Specimen K. AT2 1 in 4000 (20 x 
magnification) showing moderate positive immunostaining within the spindle-shaped myofibroblast 
cells. This image is typical of 12 different experiments on similar tissues (n=12). 
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Figure 3.30: Micrograph showing frozen section of Specimen L. AT2 1 in 4000 (50 x 
magnification) demonstrating immunopositivity within the smooth muscle in vessel wall but also 
uptake of myofibroblast cells. This image is typical of 12 different experiments on similar tissues 
(n=12). 
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3.6.4 Control 
 
 
 
 
 
 
 
 
Figure 3.31: Micrograph of kidney (control) AT2 1 in 4000 (100 x magnification). There is 
variable immunostaining in the tubular epithelial cells. A glomerulus which shows no staining is 
seen to the right of the centre. This image is typical of 12 different experiments on similar tissues 
(n=12). 
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Figure 3.32: Control specimen: Micrograph showing frozen section of Specimen L (100 x 
magnification) with the primary AT2 antibody omitted. Note no immune-positivity within 
myofibroblasts when compared to the same experiment where the primary antibody was added (Fig 3.30). 
This image is typical of 12 different experiments on similar tissues (n=12). 
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Study 7 
 
3.7  Alpha-smooth muscle actin studies 
 
3.7.1  Immunostaining of paraffin sections 
 
Positive immunostaining for myofibroblasts were present in all capsule specimens (n=12). 
Interestingly, myofibroblasts were observed to be higher in less mature capsules, although not 
specifically counted in this study. The study also showed that in some capsules, the myofibroblasts 
were dispersed diffusely throughout the capsule, but in others the myofibroblasts were more 
localised on the outer layer of the capsule, contacting the implant. 
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Figure 3.33: Micrograph showing paraffin section of Specimen H. SMA 1 in 10 (50 x 
magnification). This concentration was too high therefore more dilute concentrations were used to 
find an optimum concentration. This image is typical of three different experiments on similar 
tissues (n=3). 
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Figure 3.34: Micrograph showing paraffin section of Specimen H: SMA 1 in 50. (40 x 
magnification). In this section, with a more optimum antibody concentration, the vascular smooth 
muscle is highlighted by positive alpha-SMA immunostaining. This image is typical of ten different 
experiments on similar tissues (n=10). 
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3.7.2  Immunostaining of cryostat sections 
 
 
 
 
 
 
 
Figure 3.35: Micrograph showing frozen section of Specimen I. alpha-smooth muscle actin 1 in 50 (20 x 
magnification). The data dshow strong positive antibody uptake within stromal spindle-shaped cells. This 
demonstrates that the stromal cells that are staining with both alpha-SMA and AT2 are myofibroblasts. This 
co-staining was described by McKirdy et al, 2000. This image is typical of ten different experiments on 
similar tissues (n=10). 
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The results have clearly identified the presence of myofibroblasts in breast capsule tissue. 
Moreover, the expression of the AT1 and AT2 receptor antibodies was co-localised with the 
myofibroblast marker, for the first time demonstrating that in breast capsule, these cells contain 
both AT1 and AT2 receptors. 
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3.7.3  Control  
 
 
 
 
 
 
 
 
Figure 3.36: Micrograph showing small bowel (control). SMA 1 in 50 (100 x magnification). The 
smooth muscle component of the muscularis mucosae (short arrow) and the blood vessel (long 
arrow) walls is highlighted by the Alpha-Smooth Muscle Actin (alpha-SMA) antibody. This image 
is typical of 12 different experiments on similar tissues (n=12). 
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3.8      Comparison of immunostaining in capsule specimens 
 
 
Table 3.3: Table summarising and comparing the uptake of polyclonal antibodies against 
Angiotensin II Type 1 receptors (AT1), Angiotensin II type 2 receptors and alpha-smooth muscle 
actin in breast capsule paraffin and frozen sections in this study  
(Note: X indicates frozen section was not performed for these early specimens). 
 
 
Patient  Specimen Baker 
Grade 
Paraffin Sections Frozen Sections 
AT1 AT2 α-SMA AT1  AT2 α-SMA 
1   A III nil nil strong 
positivity 
X X strong 
positivity 
2 B IV very 
weak 
nil strong 
positivity 
X X strong 
positivity 
2  C III nil nil strong 
positivity 
X X strong 
positivity 
3 D III nil nil strong 
positivity 
X X strong 
positivity 
3 E IV nil nil strong 
positivity 
nil nil strong 
positivity 
4  F III nil nil strong 
positivity 
X X strong 
positivity 
4  G IV nil nil strong 
positivity 
X X strong 
positivity 
5  H IV weak  nil strong 
positivity 
weak strong 
positivity 
strong 
positivity 
6  I IV weak- 
moderate 
nil strong 
positivity 
weak strong 
positivity 
strong 
positivity 
6  J III nil nil strong 
positivity 
weak weak- 
moderate 
strong 
positivity 
7-  K IV nil nil strong 
positivity 
weak moderate strong 
positivity 
8-  L IV nil nil strong 
positivity 
moderate weak- 
moderate 
strong 
positivity 
Control Kidney n/a strong 
positivity 
strong 
positi
vity  
n/a strong 
positivity 
strong 
positivity  
n/a 
Control Uterus n/a n/a n/a strong 
positivity 
n/a n/a strong 
positivity 
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The results show that myofibroblasts were present in all capsules (n=12). AT1 and AT2 receptors 
were presented in 50% (n=6) of capsules (paraffin and cryostat sections) however, in the cryostat-
only group, staining was positive in 100% (n=5) of capsules. Results also showed that expression of 
these receptors was co-localised with α-sma uptake demonstrating the key components of the RAS 
are present within breast capsule myofibroblasts. A higher expression and wider distribution of AT2 
receptors was also noted compared with AT1 receptors. 
 
 
3.8  Gel contraction 
 
In this study, solidification of three-dimensional gel collagen lattices was suboptimal for consistent 
measurements of contraction to test the experimental variables. The NaOH titration stage of the gel 
contraction assay was repeated several times to explore more optimal amounts of NaOH to add to 
the collagen/media mixture. Increasing amounts of NaOH were investigated (2-10 µl).  Increasing 
concentrations of cells were also investigated in attempt to set the gels. The mixture was also left to 
solidify for increasing amounts of time 20, 40 and 60 minutes. When solidification was still 
unsuccessful longer periods of three, six, and twelve hours were tested. However, in the described 
method by Colgen, they describe rapid solidification of the gels, albeit the method being difficult. 
Despite efforts, the consistency of the gels did not reach a substantial density in order to accurately 
measure the rate of myofibroblast contraction.  
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4.1   Discussion 
 
4.1.1  Epidemiology of breast cancer in the Lancashire and Cumbria Cancer Network 
 
More women are surviving breast cancer than ever before. Over 80% of patients survive for at least 
five years after diagnosis (Clay, 2008). The latest analysis of breast cancer incidence rates 
throughout the UK reports only modest variation between most cancer networks, but notably higher 
rates in parts of south England and south-east Scotland, and lower rates in parts of London (Cancer 
Research UK, 2012). Royal Preston Hospital is part of the Lancashire and Cumbria Cancer 
Network. Recent statistics have shown that women living in the former West Cumbria Primary Care 
Trust (PCT) have the highest survival rate within the Strategic Health Authority at 83.6%. Average 
out breast cancer survival within Cumbria is 81.7% placing it above the district average of 80.6%. 
However, women living in Preston (78.4%) and Blackpool (75.7%) have the lowest survival rates 
within the Cancer Network (Clay, 2008). Heredity, obesity and certain hormonal medications may 
contribute to a woman’s risk of developing breast cancer (Cancer Research UK, 2012). 
Approximately 40% of women with breast cancer will undergo mastectomy and as mentioned 
previously, all should be offered breast reconstruction according to NICE. 
 
4.1.2  Capsular contracture disease in the study population 
 
All patients in the study underwent surgical treatment for capsular contracture disease. The patients 
were generally otherwise well with no significant co-morbidities at the time of surgery. The patients 
in the study had a mean average of 2.75 previous procedures (range 1 – 9 ± 3.37) for treatment of 
capsular contracture. This clearly demonstrates the challenges associated with treatment of this 
disease which often re-occurs despite surgical excision. Capsular contracture is recognised to have a 
higher incidence and, also be more severe, in women who undergo breast reconstruction following 
surgery for breast cancer (Handel et al, 1995). Three of the patients underwent initial breast 
augmentation following previous surgical treatment and adjuvant radiotherapy for breast cancer. All 
of these patients developed more severe, Baker Grade IV, capsular contractures. Other aetiological 
factors proposed to play a role in the formation of capsular contracture including haematoma, 
infection, silicone leakage and smoking were all also common findings amongst the study group, 
thus supporting these theories.  
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4.1.3  Capsular contracture disease 
 
All surgeons who perform augmentation mammoplasty agree that the most unpredictable and 
challenging problem associated with this popular procedure is the onset of capsular contracture. 
Encapsulation of a foreign body, such as breast implant, which is too large to be removed by 
phagocytosis, is a normal physiological phenomenon. However, the mechanisms as to why these 
biologically normal capsules contract in some patients remain poorly understood (Embrey et al., 
1999).   
This contraction of the capsule around an implant firms and distorts the appearance of the breast, 
causing significant pain and morbidity for women often undergoing this procedure following breast 
cancer surgery. Capsular contracture is also more likely if patients have radiotherapy before or after 
reconstruction with a breast implant.  This problem occurs so frequently that most Breast and 
Plastic Surgeons consider capsular contracture to be an undesirable sequelae of augmentation than 
as a complication per se (Shiffman, 2009). 
Successful prevention and treatment of capsular contracture disease are notoriously challenging. 
This potentially may be due to the lack of knowledge of the exact cellular mechanisms governing 
this phenomenon which makes targeting of pharmacological therapies difficult.  Surgery is 
currently the only recognised treatment for capsular contracture disease.   
 
4.1.4   The myofibroblast in capsular contracture 
 
The cell thought to be implicated in the formation of capsular contracture is the myofibroblast 
(Rudolph et al., 1978). First described in granulation tissue, myofibroblasts are responsible for 
wound contraction, disappearing once wound healing is complete (Gabbiani, 1992).  These cells are 
histologically similar to fibroblasts but contain smooth muscle elements that are connected to the 
extracellular matrix. These connections are thought to be the driving force of the contractile activity 
of these cells. This actin also facilitates the identification of the myofibroblast on immunological 
stains (Foo et al, 1992; Gabbiani 1992). 
In pathological wound healing, the contractile activity of myofibroblasts persist which leads to 
abnormal fibrous tissue such as in hypertrophic and keloid scarring and palmar fibromastosis in 
Dupuytren’s disease (Hinz, 2007). Similar phenomena are likely to be responsible for the fibrotic 
and contractile processes in capsular contracture. 
Rudolph et al (1978) found myofibroblasts in 20 of 25 firm contracted capsules, but also in 16 soft 
non-contracted capsules. They also found that myofibroblasts were more likely to be found in 
immature capsules, as is consistent with the regulation of the myofibroblast in other wounds.  
However, despite many experimental and clinical studies, the aetiology and pathogenesis of the 
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cellular mechanisms that regulate the contractile properties of the myofibroblast in capsular 
contracture remains poorly understood (Baker et al., 1981; Shiffman, 2009). 
 
4.1.5  The Renin-Angiotensin-System  
 
The renin-angiotensin-system (RAS), which was originally described in the context of homeostasis 
of blood pressure and water and electrolyte balance has also been shown to be a major regulator of 
the inflammatory response (Lavoie and Sigmund., 2003; Paul et al, 2006).  Angiotensin II, the 
active end product of the RAS, has been implicated as a mediator of organ fibrosis and cutaneous 
repair (Sun et al., 1996b). Ang II stimulation has been shown to regulate proliferation of skin 
fibroblasts and the production of extracellular matrix, which are important processes in skin wound 
healing and fibrosis (Liu et al., 2004). However, few studies have examined the localization of RAS 
components, such as angiotensin II receptors, renin (REN), angiotensinogen (AGTN), and 
angiotensin-converting enzyme (ACE), in fibrotic breast capsular tissue. 
 
4.1.6   Significance of angiotensin receptors 
 
Angiotensin II exerts its important physiological functions through two distinct receptor subtypes, 
type 1 (AT1) and type 2 (AT2) receptors (Busche et al., 2000). AT1 receptors mediate all well-
known effects of angiotensin II, ranging from vasoconstriction to tissue remodelling (Dudley et al., 
1990).  While the pro-inflammatory features of the angiotensin AT1 receptor are well established, 
the role of the AT2 receptor has been less well defined (Rompe et al., 2010). Most current evidence 
supports an anti-inflammatory role for AT2 receptor and expression of the AT2 receptor has been 
shown to be in injured tissues and organs undergoing remodelling. In some pathological situations, 
the effects of AT2‐receptor activation are hypothesised to antagonise those mediated through AT1 
receptors (Akazawa et al., 2012). A Ying‐Yang hypothesis has been proposed in which AT1 and 
AT2 receptors have principally contrary functions (Rompe et al., 2012). These opposed actions of 
AT1 and AT2 predispose the RAS to take part in regulatory mechanisms, which may apply to 
wound healing and the inflammatory response (Steckelings et al., 2005). 
However, this view that AT2 receptors exclusively exert beneficial effects has been recently 
challenged. In pathological models, the function of AT2 has been proposed to mimic that of AT1 
receptors, for example, in cardiac models, inducing vasoconstriction and cardiac hypertrophy 
(Rompe et al., 2012).  It could therefore be proposed that excess Ang II, which cannot bind 
anymore to the occupied AT1 receptors, then binds to the AT2 subtype and its function is no longer 
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beneficial. Given its up-regulation in various pathological conditions, the AT2 receptor remains a 
promising target for treatment. 
 
4.1.7   Aims of study 
 
Clinical studies were designed to review the aetiology and factors contributing to capsular 
contracture disease amongst the study group. The study was also designed to investigate whether 
myofibroblasts were present in the fibrous breast capsules. 
The aims of the study were to determine the presence of a local RAS in fibrotic capsular tissue 
around mammary implants. The expression of the fundamental components of the RAS, namely the 
AT1 and AT2 receptors were investigated in breast capsule tissue excised during surgery for 
capsular contracture disease. The expression of the RAS key receptors were compared with markers 
for smooth muscle actin to compare the localisation of the RAS activity with the primary cell 
involved in the formation of the fibrous capsule, the myofibroblast, and to explore the possible role 
of Ang II in capsule formation. 
This study proposed to elucidate whether modulation of the RAS may provide the basis for a safe 
and cheap therapeutic strategy with which to modify capsular contracture affecting women with 
mammary implants.  
 
 
4.1.8  Findings of the  study 
 
Histological examination of breast capsule specimens with haematoxylin and eosin stains showed 
dense fibrosis along with massive inflammatory cell infiltration The study showed that 
myofibroblasts were present in all capsules (n=12) and the fibrotic and inflammatory processes 
were associated with myofibroblast uptake.   The myofibroblast is recognised as the primary cell to 
express Ang II in other organs and its detection in all capsules supports the hypothesis that this cell 
is a key mediator of the fibrotic process in this context. Interestingly, myofibroblast levels were 
observed to be higher in less mature capsules, although not specifically measured in this study, 
suggesting that this cell may play a role in the earlier stages of capsular contracture formation and 
remodelling. Observations in the study also showed that in some capsules, the myofibroblasts were 
dispersed diffusely throughout the capsule but in others, the myofibroblasts were more localised on 
the outer layer of the capsule, contacting the implant. 
Indirect immunofluorescence was performed on the primary cells and also on paraffin and cryostat 
sections. Anti-AT1 and anti-AT2 receptor antibodies were used as the primary antibodies for 
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detection of the RAS key receptors. In this present study, the presence of Angiotensin II Type I and 
Angiotensin II Type II receptors were identified within 50% (n=12) of all (paraffin and cryostat) 
sections and 100% (n=5) of cryostat only sections from primary capsule tissue of patients with 
capsular contracture disease. AT2 receptor expression was significantly enhanced compared to that 
of AT1. AT1 and AT2 receptor expression was also found to be co-localised with areas of 
myofibroblast expression, demonstrated by the corresponding uptake of alpha- smooth muscle 
actin. Positive expression of AT1 and AT2 in the endothelial cells of the capillary vessels within the 
tissue sections also provided an inbuilt internal antibody control. 
Although detection of the AT1 and AT2 receptors in the paraffin sections, using polyclonal anti-
AT1 and AT2 receptor antibodies was weak, this may have been because of the tissue fixation 
method and/or low detection efficiency. Similarly, lack of uptake in the fibroblast culture smears 
potentially due to an antigen retrieval deficiency limitation. 
In the present study, although the level of angiotensin II was not determined, for the first time it has 
been demonstrated that the key AngII receptors, AT1 and AT2, of the RAS were expressed by the 
myofibroblast cells in breast capsular contracture tissue.  These data provide strong evidence for a 
capsular RAS within the fibrosing breast capsule, and a linkage between the RAS and capsular 
fibrogenesis, suggesting that within the capsule, AngII may be generated and, in turn, activate 
myofibroblast cells to contract in the fibrosing diseased capsule.  
The concept discussed in the literature that AT1 and AT2 receptors mediate opposed actions of Ang 
II could suggest that their up-regulation in this study does not necessarily augment the effects of 
Ang II (Steckelings et al, 2005). The results of the study could suggest that AT2 receptor expression 
is up-regulated in mature capsules to counteract the effects caused by the AT1 receptor during early 
capsule formation. The present study was not able to determine AT1 and AT2 receptor expression 
in the initial stage of capsular fibrosis as these patients do not require surgery.  The expression of 
these receptors may change as the capsule undergoes maturation and remodelling and the results 
propose that the ratio of the expression of AT1 and AT2 receptors in the capsule tissue could 
potentially determine the overall result of Ang II action. 
 
4.1.9   ACE inhibitors 
 
Angiotensin-converting enzyme inhibitors are commonly used in renal and cardiovascular diseases. 
Enalapril, an ACE-inhibitor, prevents the expression of fibrotic mediators, TGF-1 and inflammatory 
markers, anti-ED1, and anti–collagen III (Zinmann et al, 2007). Through the same processes, such 
treatment has also shown to prevent capsular contraction on mammary prostheses that have been 
implanted in rats (Zinmann et al, 2007). Given that AT1 and AT2 receptors have now been 
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demonstrated in capsular contracture tissue, from these data, therefore, it could therefore be 
proposed that the development of capsular contracture may be modulated by inhibiting the RAS 
using ACE inhibitors and AT1 and AT2 receptor antagonists.   
The use of AT-1 receptor blockers has been shown to decrease myocardial fibrosis (Busche et al., 
2000). Data on the AT2-type receptor in inflammation are still rather sparse and are somewhat 
controversial. However, the results of this study propose the potential utilisation of AT2 receptor 
stimulation also as a novel pharmacological concept in anti-inflammation. Studies are required to 
know more about the AT1 and AT2 receptors in this context and there potential application in drug 
development. 
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Chapter V 
 
 
 
 
 
Conclusion 
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5.1   Conclusions 
 
Capsular contracture is a disorder of unknown aetiology characterised by fibrosis. Several studies 
have demonstrated that the RAS plays a key role in wound healing and fibrosis. Therefore, 
therapies targeting the RAS may represent a promising paradigm for the prevention and treatment 
of capsular contracture in the setting of breast reconstruction. 
 
The goal of this study was to investigate the presence of a local RAS and the profibrotic potential of 
Ang II in capsule tissue. The study employed primary tissues isolated from twelve breast capsules 
in eight patients with capsular contracture disease. Myofibroblasts from each patient were 
successfully cultured over a period of 7-10 days to produce normal growth curves. Following 
culture, myofibroblasts were studied morphologically. Paraffin and cryostat sections were 
subsequently treated with specific antibodies for the identification of angiotensin type 1 (AT1) and 
type II (AT2) receptors. 
 
AT1 and AT2 receptors were present in 50% (n=12) of all capsules (paraffin and cryostat sections) 
and 100% (n=5) of the cryostat-only group. Receptors were co-localised within myofibroblasts. The 
AT1 and AT2 receptors were also present within the smooth muscle walls of blood vessels within 
the tissue sections which provided an inbuilt internal antibody control. A higher expression and 
wider distribution of AT2 receptors were identified in the tissue compared to AT1 receptors. 
Solidification of 3D gel collagen lattices was suboptimal for consistent measurements of contraction 
despite numerous attempts. 
 
In conclusion the results of this study have identified the presence of myofibroblasts in tissues of 
patients with capsular contracture disease and have demonstrated that they are amenable to culture 
successfully. Moreover, these myofibroblasts contain both AT1 and AT2 receptors. This co-
localisation of Angiotensin II receptors and myofibroblast expression has implications for potential 
pharmacological regulation of capsular contracture disease which, until now has not been 
responsive to safe, effective pharmacological therapy. Further experiments are required to study the 
role of blocking AT1 and AT2 receptors excitation-contraction coupling process of the 
myofibroblasts. 
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5.2  Scope for future work 
 
1. Breast capsule myofibroblasts can be cultured as has been demonstrated. The molecular 
mechanism of myofibroblast differentiation and function needs to be clearly understood in 
order to eradicate this key cell in pathological tissue contractures. Novel strategies and 
pharmacological drug therapies are required to target the actions of the myofibroblast.  
2. It is also possible to study the morphology of the primary tissues and the myofibroblasts 
using phase contrast and electro-microscopy. Further studies into the myofibroblasts in breast 
capsule are required, particularly pattern of localisation and myofibroblast count in relation 
post-operative age of capsule (i.e. maturity), thickness and Baker’s classification. 
3. Little is known regarding the RAS components within breast capsule. The localisation and 
expression levels of other components of RAS: REN, AGTN, and ACE, are yet to be 
determined in the fibrosing capsule, and to what extent the system is involved in abnormal 
capsule formation.  
4. The presence of AT1 and AT2 receptors has been clearly demonstrated in breast capsule in 
this study. Future work should determine what consequences alterations in receptor 
expression may have in this context and whether the expression of AT1 and AT2 receptors 
are affected by administration of ACE- inhibitors.  
5. It may also possible to employ binding studies to identify angiotensin receptors in the tissues 
and cells using radio-labelled angiotensin. The levels of such receptors in capsules of 
different maturity could be investigated using flow cytometry. 
6. In the literature it has been possible to measure contraction in the myofibroblasts using 
different physiological methods. A video-edge system in conjunction with three-dimensional 
collagen gel can be used to measure contraction. The cells can be treated with different drugs 
and their respective antagonists to study their effects on contraction. If the effects of 
angiotensin II are blocked using an angiotensin-converting enzyme inhibitor, the 
inflammatory and fibrotic processes may be attenuated, which may be demonstrated by a 
reduced rate of contracture. 
7. A histological classification for capsular contracture is also needed to describe precisely the 
morphological changes in capsular contracture such as age of the collagen fibres, presence of 
synovia-like metaplasia on the inner surface of the capsule, number of histiocytes, giant cells, 
and other inflammatory cells, silicone levels and foreign body granulomas. Such a 
classification would allow a more accurate comparison of techniques and therapeutic 
interventions then current subjective clinical classifications. 
8. Measure intracellular calcium in myofibroblasts to investigate the role of calcium in the 
process of contraction in the myofibroblast.  
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7.1  Patient Information Sheet 
 
PATIENT INFORMATION SHEET 
 
STUDY TITLE: THE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME (ACE)-INHIBITORS 
ON CAPSULAR CONTRACTURE AROUND MAMMARY IMPLANTS. 
 
Simplified Title: Study to test the effect of drugs on scar tissue (capsular contracture) around 
breast implants.  
 
You are being invited to take part in a research study. Before you make a decision on 
whether you would like to participate it is important for you to understand why the research 
is being done and what it will involve. 
 
Please take time to read the following information carefully  
 
Please ask us or your consultant plastic surgeon if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish to take part 
and discuss it with others if you wish.  Please keep this information sheet for future 
reference. Thank you for reading. 
 
What is the purpose of the study? 
 
Capsular contraction around breast implants is very difficult to prevent or treat. Treatment of 
capsular contracture usually requires surgery to remove the ‘capsule’ as there are currently no 
medicines to treat this condition.  
Angiotensin-Converting Enzyme (ACE)-Inhibitors is the medical name for drugs commonly 
used in heart and kidney disease to reduce scarring and fibrosis. Our study aims to determine 
whether these drugs can also be used to prevent scarring and fibrosis around breast implants. The 
study aims to try to develop a medicine to treat capsular contracture affecting breast implants that 
are commonly used for women having breast reconstruction or enlargement.  
 
What does taking part involve? 
 
We are asking for patients to donate scar tissue that is normally removed during treatment for 
capsular contracture. We would use this tissue for the research to test the drugs. NO extra tissue 
will be taken for the study, only tissue which would be removed as part of your routine surgery 
would be used. Taking part in this study would not mean any changes to your routine treatment  
 
What will happen to the samples? 
 
The samples will be taken to laboratories at Royal Preston Hospital and the University of Central 
Lancashire where we will conduct experiments to tests the effects of drugs. The researcher and 
their clinical supervisors will have access to the samples. NO tissue will be stored and any tissue 
not used will be disposed of according to hospital policies. The samples will not be used for any 
other research. 
 
Do I have to take part? 
 
It is entirely your decision whether or not to take part. If you do wish to take part you will be given 
this information sheet to keep and will be asked to sign a consent form (you will also be given a 
copy of the signed consent form to keep). You are still free to withdraw at any time without giving a 
reason. If you decide not to take part or withdraw at any time this will not affect the standard of 
care you receive. 
 
What will happen to me if I take part? 
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Taking part in the study will not alter you routine surgery in any way. You WILL NOT be required to 
have any extra hospital visits or have any extra investigations. The study only involves tests on the 
samples being donated.  
 
What is being tested? 
 
Angiotensin-Converting Enzyme (ACE)-Inhibitors such as Enalapril are drugs commonly used in 
kidney and heart disease to prevent scarring and fibrosis. Our study aims to determine whether 
these drugs could also be used to treat capsular contracture. 
 
What are the disadvantages or risks associated with taking part? 
 
There are NO disadvantages or risks specifically related to taking part in the study. The risks 
associated with your routine surgery will have been discussed separately with you by your 
consultant. 
 
What are the possible benefits of taking part? 
 
There is no medical benefit from taking part in the study and it will not affect the outcome of your 
surgery. The study aims to develop a drug treatment for capsular contracture affecting breast 
implants that are commonly used for women having breast reconstruction or enlargement. 
 
Will my taking part in the study be kept confidential? 
 
All information which may be collected will be kept strictly confidential. Any information about you 
which leaves the hospital will have your name, age, address and all personal information (including 
patient/hospital/NHS number) removed so that you cannot be recognised from it. 
 
What will happen to the results of the study? 
 
The results of the study will be submitted for publication in scientific journals. You may receive 
information about the results of the study upon request. 
 
Who is funding the research? 
 
The research will be funded by the Rosemere Cancer Foundation. 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests.This study has been reviewed and given a favorable opinion 
by: North West 8 Research Ethics Committee- Greater Manchester East and Lancashire 
Teaching Hospitals Trust Ethics Committee. 
 
What arrangements will be made for insurance/ indemnity?  
 
Patients will not be exposed to any risks associated with participation in this research however, 
NHS indemnity will apply and in the event that something does go wrong and you are harmed 
during the research and this is due to someone‘s negligence then you may have grounds for a 
legal action for compensation against (Lancashire Teaching Hospitals, NHS Trust,) but you may 
have to pay your legal costs.  
 
What happens if there is a problem or I am unhappy about the study? 
If you have any questions or concerns about the study you can speak to us (the researchers) who 
will do our best to answer your questions. Hopefully, we will be able to sort out your concerns very 
quickly.  However, if you remain unhappy and wish to make a formal complaint related to the study 
you may do this in writing. Your letter should be addressed to the Chief Executive of Lancashire 
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Teaching Hospitals NHS Foundation Trust at the following address: Royal Preston Hospital, 
Sharoe Green Lane, Fulwood, Preston, PR2 9HT. This will not affect your treatment in any way. 
You could also seek advice from the Patient Advice and Liaison Services (PALS) at Royal Preston 
Hospital which provides support to patients, their families and visitors (contact details for PALS are 
listed below). 
Thank-you for reading. 
 
Contacts for further information: 
 
Dr Leila. Touil (Researcher) 
Plastic Surgery Department 
Royal Preston Hospital 
Sharoe Green Lane 
Fulwood, 
Preston 
PR2 9HT 
Tel: 01772522847  
Email: Leila.Touil@lthtr.nhs.uk 
 
Patient Advice and Liaison Services (PALS) 
Royal Preston Hospital, 
Sharoe Green Lane,  
Fulwood,  
Preston, 
PR2 9HT 
Tel: 01772 522972 
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7.1.3. Study consent form 
 
 
CONSENT FORM 
 
Centre Number: 
 
Study Number: 09/H1013/58 
 
Patient Identification number for this study: 
 
Title of Project: THE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME (ACE)-INHIBITORS ON 
CAPSULAR CONTRACTURE AROUND MAMMARY IMPLANTS. 
 
Simplified Title: Study to test the effect of drugs on scar tissue (capsular contracture) around breast implants.  
 
 
Name of Researcher: Dr Leila Touil 
 
         Please initial box 
 
1. I confirm that I have read and understand the information  
sheet dated September 2009 (Version 2) for the above study.   
I have had the opportunity to consider the information, ask  
questions, and have these questions answered properly. 
 
2. I understand that my participation is voluntary and that  
I am free to withdraw at any time without giving any reason, 
without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and 
data collected during the study, may be looked at by the 
researchers, from regulatory authorities or from 
the NHS trust, where it is relevant to my taking part in this  
research. I give permission for these individuals to access my 
records. 
 
4. I agree to take part in the above study. 
 
 
 
Name of Patient Date   Signature 
 
Name of Person Date   Signature 
taking consent 
 
When completed: 1 for participant, 1 for researchers site file original to be kept in medical notes 
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Study Patients: Summary of Previous Breast Surgery 
Patient Previous Breast Surgery Complications 
1  1997 Bilateral Breast Augmentation 
 
 1997 Left breast haematoma returned 
to theatre for evacuation 
2 
 
 1998 Bilateral breast augmentation 
 1999 Bilateral exchange of implants 
and capsulectomies 
 1999 Left side implant replacement 
 2002 Right side implant replacement 
and capsulectomy 
 
 1999 Left implant infection returned 
to theatre for removal of implant (pus 
in cavity) and washout of pocket 
 2001 Right side implant infection 
treated with intravenous antibiotics 
 2002 Further right implant low grade 
infection managed surgically with 
right side washout, implant 
replacement and capsulectomy 
3 
 
 1984 Bilateral breast augmentation 
 1987 Bilateral closed capsulotomies 
 1988 Exchange of bilateral implants 
 1991 Exchange of bilateral implants 
 1992 Capsulotomy right breast 
 1995 Subtotal capsulotomy right breast 
 1997 Capsulotomy right breast 
 2006 Bilateral exchange of implants 
and capsulectomies 
 1988 Right side implant infection- 
returned to theatre for exchange of 
implants 
4 
 
 2006 Wide local excision and axillary 
node clearance right breast 
 2006 Adjuvant radiotherapy 
 2007 right side breast augmentation 
 2007 removal of right ruptured implant 
 2008 Bilateral breast augmentation 
 2007 Right side ruptured implant- 
returned to theatre for removal and 
washout of cavity. Implant not 
replaced. 
5 
 
 1980 Multiple lumpectomies right 
breast (histology showed benign 
disease) 
 1982 Bilateral breast augmentation 
 1999 Bilateral mastopexies 
 2001 Bilateral exchange of  implants 
 
6 
 
 2004 Wide local excision left breast 
(incompletely excised) 
 2004 Further wider excision 
 2004 Adjuvant radiotherapy 
 2006 Bilateral breast augmentation 
 
7  2007 Bilateral breast augmentation for 
congenital asymmetry 
 2011 Insertion larger left breast 
implant for asymmetry 
 2011 Evacuation left breast haematoma 
 2011 Post op haematoma left breast- 
returned to theatre for evacuation. 
Implant replaced. 
8 
 
 2006 Right breast skin sparing 
mastectomy and immediate implant 
reconstruction 
 2006 Adjuvant radiotherapy 
 
Figure 4.1: Previous breast surgery including treatments for capsular contracture and 
complications.  
 
